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ABSTRACT
PKC ISOZYMES IN LUNG CANCER DEVELOPMENT AND THERAPY RESISTANCE
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Marcelo G. Kazanietz, Ph.D.
Non-small cell lung cancer (NSCLC) is one of the major causes of cancer related mortality worldwide and
comprises the most frequent type of lung cancers. Oncogenic alterations such as activating mutations in the
epidermal growth factor receptor (EGFR) and KRAS have been implicated in the pathogenesis of NSCLC.
Protein kinase C (PKC), a family of serine/threonine kinases that are targets of phorbol ester/diacylglycerol,
has been shown to be involved in EGFR and KRAS signaling, indicating their importance in lung cancer
progression. In this thesis work, we established the requirement of PKCα and PKCε in the malignancy of lung
cancer in the context of EGFR and KRAS mutations. Using an isogenic model system, we found NSCLC cells
that are resistant to the EGFR-tyrosine kinase inhibitor erlotinib display remarkably high levels of PKCα
compared to the parental erlotinib sensitive cells. Inhibition of PKCα resulted in sensitization to erlotinib
treatment and loss of gene expression associated with mesenchymal phenotype. Additionally, we showed that
PKCα signaling controls activation of a key regulator of lung cancer progression, NF-κΒ. PKCα depletion by
RNA interference in lung cancer cells indeed attenuates IκΒα phosphorylation, subsequent impairment of
NF-κΒ translocation into the nucleus, and induction of NF-κΒ target genes in response to interleukin 1 beta
(IL-1β). Finally, in the context of KRAS mutation, we presented evidence showing the requirement of PKCε
signaling for the formation of KRAS-driven lung tumors in vivo. Tumor formation in the double transgenic
KRASG12D;PKCε-/- mice was remarkably reduced compared to KRASG12D;PKCε+/+ mice. All together,
this thesis work highlights the multiple roles that PKC isozymes play in the initiation and progression of lung
cancer, and suggests a potential therapeutic role for PKCα and PKCε inhibitors for prevention and treatment
of lung tumors.
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ABSTRACT 
 
PKC ISOZYMES IN LUNG CANCER DEVELOPMENT AND THERAPY 
RESISTANCE 
 
Mahlet B. Abera 
 
Marcelo G. Kazanietz, Ph.D. 
 
Non-small cell lung cancer (NSCLC) is one of the major causes of cancer related 
mortality worldwide and comprises the most frequent type of lung cancers. Oncogenic 
alterations such as activating mutations in the epidermal growth factor receptor (EGFR) 
and KRAS have been implicated in the pathogenesis of NSCLC. Protein kinase C (PKC), 
a family of serine/threonine kinases that are targets of phorbol ester/diacylglycerol, has 
been shown to be involved in EGFR and KRAS signaling, indicating their importance in 
lung cancer progression. In this thesis work, we established the requirement of PKCα and 
PKCε in the malignancy of lung cancer in the context of EGFR and KRAS mutations. 
Using an isogenic model system, we found NSCLC cells that are resistant to the EGFR-
tyrosine kinase inhibitor erlotinib display remarkably high levels of PKCα compared to 
the parental erlotinib sensitive cells. Inhibition of PKCα resulted in sensitization to 
erlotinib treatment and loss of gene expression associated with mesenchymal phenotype. 
Additionally, we showed that PKCα signaling controls activation of a key regulator of 
lung cancer progression, NF-κΒ. PKCα depletion by RNA interference in lung cancer 
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cells indeed attenuates IκΒα phosphorylation, subsequent impairment of NF-κΒ 
translocation into the nucleus, and induction of NF-κΒ target genes in response to 
interleukin 1 beta (IL-1β). Finally, in the context of KRAS mutation, we presented 
evidence showing the requirement of PKCε signaling for the formation of KRAS-driven 
lung tumors in vivo. Tumor formation in the double transgenic KRASG12D;PKCε-/- mice 
was  remarkably reduced compared to KRASG12D;PKCε+/+ mice. All together, this thesis 
work highlights the multiple roles that PKC isozymes play in the initiation and 
progression of lung cancer, and suggests a potential therapeutic role for PKCα and PKCε 
inhibitors for prevention and treatment of lung tumors. 
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1.1 Lung cancer 
 
Lung cancer is the largest contributor to new cancer diagnosis and cancer-related 
death each year [57]. Most lung cancer patients have advanced disease at the time of 
diagnosis, shortening the 5-year survival rate to only 10-15 %. On the basis of histology, 
lung cancers are classified as small cell lung carcinoma (SCLC) and non-small cell lung 
carcinoma (NSCLC). NSCLC comprises 80 % of lung cancer cases and is further sub-
divided into adenocarcinomas (50 %), squamous cell carcinoma (35 %) and large cell 
carcinoma (15 %). Small cell lung carcinomas and squamous cell carcinomas arise from 
the central compartments of the lung, while adenocarcinomas arise from the progenitor 
cells of the bronchioles (Clara cells), alveolar type II cells, or from mucin producing cells 
in the peripheral compartment of the lungs (Table 1.1) [24, 162].  
Lung tumorigenesis involves a series of progressive pathological changes in the 
mucosa membrane lining the respiratory tract. In squamous cell carcinoma development, 
the bronchial epithelium undergoes a series of morphological changes that represent cell 
transformation from normal into precursor lesions, including hyperplastic, metaplastic, 
and dysplastic lesions. While hyperplasia and squamous metaplasia are considered 
reversible changes, dysplastic lesions are most frequently associated with the 
development of squamous cell lung carcinomas. Similarly, adenocarcinomas develop as a 
result of transformation from premalignant precursor lesions to carcinoma in situ. 
However, in the case of adenocarcinomas, the only known precursor lesion is atypical 
adenomatous hyperplasia [62, 65, 205].  
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Tumor 
type 
Tumor subtype 
 
Incidence Location 
NSCLC Adenocarcinoma 40 % Outer edge of lungs, from mucus 
producing cells 
Squamous cell 
carcinoma 
25 % Central compartment, from cells that line 
the airways 
Large cell carcinoma 15 % Any area of the lung 
SCLC  15 % In the bronchi near the center of the 
chest 
 Others/mixed 5  % Mixed 
 
Table 1.1 Histological classification of lung cancer 
 
Lung cancer is commonly classified as small cell carcinoma (SCLC) and a heterogeneous 
group of non-small cell carcinomas (NSCLC), which includes adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma. SCLCs arise in the central 
compartment of the lungs, while NSCLCs commonly arise in the peripheral regions of 
the lungs.  
 
Tobacco smoke is the main cause of lung cancer with 80-90 % arising in cigarette 
smokers. However, in spite of the exposure to carcinogens, only 10-15 % of heavy 
smokers ultimately develop the disease, which reflects the role of genetic factors in 
predisposing to lung cancer [20]. The concept of field of cancerization has been described 
to elucidate the implication of tobacco smoke in cancer initiation. Exposure to tobacco 
smoke creates injury in the airway epithelial cells leading to development of field of 
cancerization with genetically and epigenetically altered cells. Field of cancerization 
consists of tissue adjacent to neoplastic lesions that display normal histology, but harbors 
molecular abnormalities similar to tumors [37]. There are three major theories describing 
the origin of smoking-related field of cancerization in lung tumorigenesis. One, injury 
due to cigarette smoke causes a single mutant epithelial cell clone that expands and 
extends into the respiratory lining. Second, exposure to carcinogens in cigarette smoke 
damages the entire airway tract and results in random genetic mutations in multiple areas 
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that arise from polyclonal tumor stem cells.  The third theory is that once the tumor is 
initiated, the cancer itself affects the surrounding tissue, contributing to alterations 
including oncogenic activations, tumor suppressor gene (TSG) silencing, and widespread 
loss of heterozygosity leading to malignancy [62, 113, 170]. 
 
Key genetic and epigenetic changes in NSCLC 
 
1. Genetic susceptibility 
A number of genetic polymorphisms that make smokers susceptible to lung cancer 
have been identified. For the most part, polymorphisms have been associated with genes 
encoding proteins involved in the metabolism, detoxification and gene repair due to 
tobacco smoke carcinogens. Polymorphism in CYP1A1, an enzyme that catalyzes the 
bioactivation of polyaromatic hydrocarbons (PAH), contributes to tobacco-induced 
cancers through their enhanced carcinogen-activating capacity [78]. Polymorphism in 
CYP2E1, an enzyme involved in the activation and metabolism of alcohols and 
nitrosamines, is also implicated in tobacco-induced carcinogenesis. Using human lung 
autopsies, studies correlated higher 7-methyl-dGMP adducts caused by tobacco smoke 
with the presence of CYP2E1 minor alleles [72]. CYP2A6 is another enzyme thought to 
be responsible for nitrosamine and nicotine metabolism and has been an important target 
of research on CYP family gene polymorphisms in relation to lung carcinogenesis. Large 
size clinical studies also indicate that deletion-type polymorphism at the CYP2A6 locus 
reduces the risk of lung cancer [78].  
Similarly polymorphism in genes associated with detoxification of carcinogens are 
linked to lung cancer development. Incidence of polymorphisms in glutathione S-
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transferase genes (GSTM1, GSTT1, GSTP1 or GSTM3) results in defective enzymatic 
activity that lead to increased accumulation of carcinogens. Such accumulation entails 
increased rate of PAH DNA adducts as well as higher rate of mutations within specific 
genes implicated in the cell cycle and differentiation [79]. Moreover, the risk of lung 
cancer increases dramatically in tumor samples that exhibit combinational 
polymorphisms [199]. 
Genetic defect in DNA repair genes is another factor that makes smokers susceptible 
to lung cancer. Under normal circumstances, DNA repair mechanisms prevent the 
accumulation of multiple genetic alterations that could potentially lead to cancer 
development. Specifically, studies linked hOGG1 polymorphisms to lung cancer 
incidence both in squamous cell lung carcinoma and adenocarcinomas of the lung [211, 
218]. hOGG1 is a base excision repair protein that removes a mutagenic base product (8-
Oxo-2'-deoxyguanosine) that develops from exposure to tobacco smoke, which produces 
free radicals in the respiratory tract. If repair is inadequate, DNA damage from these free 
radicals results in mutations predisposing smokers to lung cancer [173]. 
2. Loss of tumor suppressor genes 
Silencing of TSGs is a common event in cancer. TSGs are inactivated in a two-
step process that results in the loss of both gene alleles. Initially, mutations or epigenetic 
silencing inactivates one allele followed by loss of a region of the chromosome by 
deletion or mitotic recombination through a process called loss of heterozygosity [93]. 
Common TSGs inactivated in lung cancer include TP53, Rb1, P16 and PTEN. 
The p53 pathway: There is a positive correlation between tobacco use and inactivating 
mutations in the p53 TSG [77]. The p53 gene is located on chromosome 17p13 and 
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encodes for a 53-kDa phosphoprotein [20]. p53 acts as a transcriptional regulator 
implicated in the cell cycle, DNA repair, and apoptosis. During cellular stress, it induces 
the expression of the cyclin-dependent kinase (CDK) inhibitor p21cip1, which results in 
the G1 cell cycle arrest associated with either DNA repair or apoptosis [36]. p53 was 
shown to prevent the accumulation of DNA damage by activating DNA repair genes such 
as GADD45. In situations where the damage could not be repaired, p53 promotes the 
expression of pro-apoptotic genes such as BAX and Fas [139, 219]. Hemizygous deletion 
of the TP53 gene occurs in 65 % of NSCLC, more commonly in squamous cell 
carcinoma than adenocarcinomas, and it is associated with male gender, higher tumor 
grade and overall unfavorable prognosis in lung cancer [77, 189]. 
The p16/CDK-cyclin D/Rb pathway: The retinoblastoma (Rb) TSG is located on 
chromosome 13q14 and encodes a 110-kDa phosphoprotein. pRb prevents the transition 
from G1 to S phase of the cell cycle by sequestering the transcription factor E2F. This 
inhibition is however released upon phosphorylation of Rb mediated by complexes of 
cyclin D and CDK4/CDK6, which enables cells to enter the S phase in the cell cycle [69, 
161]. Although alterations in Rb expression are observed in subsets of NSCLC, the most 
striking is the loss of p16 protein upstream of Rb. p16 inhibits the formation of CDK-
cyclin D complexes, thus leading to decreased phosphorylation of Rb. Hence, loss of p16 
results in release of E2F upon Rb phosphorylation and progression into S phase of the 
cell cycle [148]. Loss of p16 function in NSCLC cells is attributed to several 
mechanisms. NSCLC cells display homozygous or heterozygous deletion within the 
coding region of p16. Additionally, hypermethylation of the 5’-CpG island in the 
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promoter region leads to gene silencing [46, 58].  In addition to the loss of Rb and p16 
functions, overexpression of cyclin D1 has also been observed in NSCLC [143]. 
PTEN: Phosphate and tensin homolog (PTEN) is a tumor suppressor gene located on 
chromosome 10. PTEN removes the phosphate from the PI3K product 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) to generate phosphoinositide 4,5-
biphosphate (PIP2). The decrease in PIP3 attenuates the recruitment of kinases such as 
phosphoinositide-dependent kinase-1 (PDK-1), which in turn phosphorylates Akt. Loss 
of PTEN expression leads to continuous Akt activity resulting in cell proliferation and 
multitude of anti-apoptotic signals [39, 169]. In contrast to other cancers, mutations or 
homozygous deletions in the PTEN gene are not common in NSCLC. However, 
approximately 70 % of NSCLC have reduced or loss of PTEN expression. These results 
suggest that the loss of PTEN expression in NSCLC is regulated at the transcriptional or 
translational level [166, 188]. 
3. Activation of oncogenes 
Unlike inactivation of TSG that involves deletion of both alleles, oncogenes are 
activated by mechanisms that target one allele and entail gene amplifications or point 
mutations. Several oncogenic dysregulations have been documented in lung cancer 
involving KRAS, EGFR, ALK, HER2, MET, PIK3CA, BRAF and ERK (Fig. 1.1). The 
following introduction only covers the two most commonly mutated oncogenes in 
NSCLC: KRAS and EGFR. 
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Figure 1.1 Frequency of mutations and amplifications of major oncogenes in 
NSCLC 
Approximately 20 % of lung adenocarcinomas harbor EGFR mutations. KRAS mutations 
are more frequently found in adenocarcinomas (30 %), which are mutually exclusive with 
EGFR mutations. A subset of adenocarcinoma harbors a transforming fusion gene, 
EML4–ALK (5 %). The mutation frequency of BRAF is 2 %, PIK3CA 3 %, and 
amplifications of MET and HER2 1 % and 2 %, respectively. Nearly 35 % of lung 
adenocarcinomas do not harbor currently detectable mutations. 
 
 
KRAS: Mutations in the KRAS gene have been found in approximately one-third of lung 
adenocarcinoma patients. KRAS is a member of the RAS family of small GTPases, 
which also includes NRAS and HRAS. The RAS proteins contain a highly conserved N-
terminal domain implicated in GTP binding, hydrolysis, and interaction with downstream 
effectors. On the other hand, the C-terminus contains domains that are highly variable 
and important for post-translational modifications [202]. Activation of RAS begins upon 
stimulation of upstream receptors such as receptor tyrosine-kinases (RTKs), which leads 
others or no 
mutation 
detected, 35% 
KRAS, 30% 
EGFR, 20% 
ALK, 5% 
BRAF, 2% 
HER2, 2% PIK3CA, 
3% 
MET, 1% ERK, 1% 
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to interaction of adapter proteins such as Grb2 with the intracellular domain of RTKs, 
and in turn recruits guanine nucleotide exchange factors (GEFs) such as SOS. GEFs 
interact with RAS to promote the exchange of GDP to GTP. Once bound to GTP, RAS 
proteins activate a large number of downstream effectors implicated in proliferation (e.g. 
RAF) and survival (e.g. PI3K) [41, 87]. 
 KRAS is the most commonly mutated RAS protein in lung cancer. KRAS 
mutations impair the intrinsic GTPase activity resulting in continuously activated GTP 
bound KRAS. Most mutations occur in exon 2 and 3, mainly at codon 12, sometimes at 
codon 13, and more rarely at codon 61 [41, 153]. KRAS mutations are mainly seen in 
adenocarcinomas of the lung with a history of smoking. The common nucleotide 
transversions in lung adenocarcinoma (G to T) are frequent in KRAS mutations and are 
associated with smoking [150].  
Meta-analysis of various studies indicates that KRAS mutations are negative 
prognostic factors for survival of lung cancer patients [132]. It has been reported that 
NSCLC patients with wild-type KRAS respond better to chemotherapeutic agents such as 
cisplatin and vinorelbine compared to patients with mutant KRAS [52, 174]. 
Additionally, KRAS mutations, which are mutually exclusive with EGFR mutations, are 
associated with lack of response to EGFR tyrosine-kinase inhibitors [180, 213]. Some 
studies also reported a lack of significant correlation between KRAS status and disease-
free progression of NSCLC patients. It has been suggested that rather than having a wild-
type KRAS or mutant KRAS, specific types of mutations are better predictors in 
determining response to therapy and prognosis [174]. 
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The Epidermal Growth Factor Receptor (EGFR): Alterations of EGFR are implicated in 
the pathogenesis of many tumors, including NSCLC. EGFR encodes an extracellular 
ligand-binding domain, a transmembrane domain, and an intracellular region consisting 
of a highly conserved tyrosine-kinase domain. Ligand binding induces homodimerization 
or heterodimerization of the receptor with other members of the EGFR family, resulting 
in autophosphorylation of the tyrosine residues. These phosphorylated tyrosine residues 
provide a docking site for SH2 (Src homology) or PTB (phosphotyrosine binding) 
domain containing adaptor proteins. EGFR is involved in the regulation of numerous 
cellular processes such as cell proliferation, survival, differentiation, invasion and 
metastasis. Overexpression of EGFR and its ligand, the transforming growth factor alpha 
(TGFα), or activating mutations in EGFR, lead to activation of signaling pathways 
including the RAS/RAF/MEK/ERK pathway, the PI3K/Akt/mTOR pathway, and the 
stress activated pathway involving JAK and STAT [140].  
 Overexpression of EGFR or its ligand TGFα occurs in 50-80 % of NSCLC, 
specifically in squamous cell carcinomas and its precursor lesions whereas EGFR 
activating mutation are more frequent in adenocarcinomas, women, East Asians 
background, and people who never smoked. Activating mutations of the EGFR have been 
reported in 15-50 % of NSCLC patients (15 % in the case of Caucasian patients and 50 % 
of East Asian patients). These mutations are often oncogenic and force the mutated cells 
to become addicted on EGFR for survival [95, 187, 213, 215]. Several activating 
mutations in the EGFR gene have been described. The two most common are a short-
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frame deletion of exon 19 (delE746-A750) and a point mutation (CTG to CGG) in exon 
21 that results in substitution of leucine by arginine at codon 858 (L858R) [94]. 
 
EGFR targeted therapies for NSCLC 
 
Monoclonal antibodies to the EGFR and small molecule tyrosine-kinase inhibitors 
are in clinical use for lung cancer patients. Monoclonal antibodies including cetuximab, 
matuzumab, panitumumab, and necitumumab bind to the extracellular domain of EGFR 
and competitively block ligand binding. The antibody-receptor complex formation is 
followed by internalization and degradation of the complex, leading to downregulation of 
EGFR signaling [57, 85]. The small molecule EGFR TKIs such as gefitinib and erlotinib 
compete reversibly with ATP for binding to the intracellular catalytic kinase domain. The 
efficiency of these drugs for blocking receptor activity and decreasing cell viability is 
significantly higher in cells harboring mutant EGFR (Fig. 1.2) [3].  
Preclinical studies have shown that both anti-EGFR antibodies and EGFR-TKIs 
block the in vitro growth of human NSCLC cell lines by inhibiting receptor 
phosphorylation and downstream protein phosphorylation, including MAPKs and Akt 
[3]. Moreover, the two classes of inhibitors have been assessed in combination with 
conventional cytotoxic chemotherapeutic drugs or radiation therapy. EGFR monoclonal 
antibodies have been shown to synergize with cisplatin or doxorubicin in NSCLC 
xenograft models. These antibodies also synergize with radiation and paclitaxel in both in 
vitro and in vivo studies. However, in the case of the small molecule inhibitors, neither 
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gefitinib nor erlotinib showed improved response rate or disease-free progression when 
used in combination with chemotherapeutic agents [24, 85]. 
 
 
 
 
Figure 1.2 Antibodies and small molecules intercepting EGFR signaling 
Anti-EGFR monoclonal antibodies and small molecule EGFR TKIs have been used in 
lung cancer treatment. mABs bind to the extracellular domain of EGFR and compete with 
endogenous ligands for receptor binding, and block ligand-induced receptor activation. 
The small molecule EGFR inhibitors compete with ATP to bind the catalytic domain of 
the kinase, which in turn inhibits EGFR autophosphorylation and downstream signaling.   
EGFR 
Cetuximab 
Panitumumab 
Matuzumab 
TKI 
Erlotinib 
Gefitinib 
PKI-166  
Lapatinib 
EKB-569 
CI-1033 
mAB 
Ligand Ligand 
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Resistance to EGFR inhibitors in NSCLC 
 
Despite the initial success of TKIs for the treatment of lung cancer patients harboring 
EGFR activating mutations, most patients develop resistance over time and progress to 
advanced stages of the disease. Several mechanisms have been reported for this acquired 
resistance, including secondary mutations in EGFR, parallel pathway activation, 
phenotypic transformation, and additional genetic alterations.  
1. Presence of secondary mutations in EGFR 
Secondary mutations in EGFR are documented in patients that develop resistance to 
EGFR TKIs. The most common is the T790M activating point mutation in exon 20 that 
substitutes the gatekeeper methionine for threonine, which interferes with the binding of 
reversible TKIs. The T790M substitution changes the affinity of the drug to the ATP 
pocket and enables ATP binding at the level of the wild-type EGFR. T790M is found in 
about 50 % of patients who developed acquired TKI resistance [94]. The use of second-
generation TKIs such as afatinib and neratinib, which irreversibly bind to EGFR have 
been evaluated to overcome the effect of acquired resistance. Although the results from 
preclinical studies have been encouraging, the drugs did not increase response rate and 
progression free survival of lung cancer patients [43, 96, 158].  
2. Parallel activation of downstream signaling pathways 
Resistance to EGFR TKIs could also be acquired through mechanisms that involve 
activation of EGFR downstream targets such as Akt and ERK independent of EGFR. 
These mechanisms mainly involve amplifications of the MET oncogene and 
overexpression of its ligand, hepatocyte growth factor (HGF). These dysregulations 
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bypass inhibition of EGFR and render resistance to TKIs [44, 152]. MET is a tyrosine-
kinase receptor implicated in cell motility, growth and angiogenesis in various tumors. 
Overexpression of HGF or MET amplification has been reported in close to 20 % of lung 
tumors exposed to EGFR TKIs. MET receptor activation results in EGFR-independent 
phosphorylation of ErbB3 and downstream activation of the PI3K/Akt pathway. This 
process allows the survival of cells with MET amplification in the presence of the EGFR 
TKI. MET amplification can occur either with or without EGFR T790M mutation. 
Although ~ 60 % of MET amplifications occur without the T790M mutation, studies 
have also reported a complementary role of the two dysregulations [14]. 
3. Phenotypic transformation - epithelial to mesenchymal transition 
During embryonic development a balance between epithelial to mesenchymal 
transition (EMT) and mesenchymal to epithelial transition (MET) maintains proper cell 
morphology. Epithelial cells are polarized with tight connection to adjacent cells whereas 
mesenchymal cells exhibit a spindle-like morphology. In the context of cancer, EMT is 
marked by loss of epithelial cell junction proteins such as E-cadherin and gain of 
mesenchymal markers such as vimentin [191]. Mesenchymal type cells also possess 
enhanced motility and invasive phenotype, and the expression of genes associated with 
EMT has been correlated with poor patient prognosis in NSCLC [21, 209]. Studies have 
found that up-regulation of Notch-1 induces mesenchymal phenotype in lung cancer cells 
that are resistant to TKIs. Moreover, inhibition of Notch-1 signaling augmented 
sensitivity to TKI [210]. The aberrant expression of transforming growth factor (TGF-β) 
is also a potent inducer of EMT [160, 212]. Erlotinib-resistant NSCLC cells with 
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mesenchymal phenotype possess high levels of TGF-β expression. In addition, blockade 
of TGF-β signaling in combination with EGFR inhibition was shown to have synergistic 
effects on EGFR inhibition and cell viability [212]. 
4. Acquired genetic alterations other than EGFR mutations 
PIK3CA mutations - Studies indicate that 5 % of lung cancers that developed acquired 
resistance to TKIs have PIK3CA mutations [159]. In several clinical trials, the 
combination of a pan-PI3K inhibitor with gefitinib resulted in enhanced efficacy in 
patients with acquired resistance to EGFR TKIs. However, many of the patients had 
toxicities, underscoring the challenge of blocking the two pathways that are critical for 
cell survival [51]. 
HER2 amplification: Mutations (approximately 2 %) and amplifications (2-5 %) of 
HER2, a member of the EGFR family, have been reported in patients with lung 
adenocarcinomas. Dysregulation of HER2 in lung cancer is associated with females, non-
smokers, and Asian backgrounds. Additionally, 12 % of lung cancer patients exposed to 
TKI have amplification of the HER2 gene and present a more advanced stage of the 
disease. HER2 amplification was also shown to be mutually exclusive with EGFR 
T790M mutations [115]. 
ERK2 amplification: Approximately 5 % of tumors resistant to TKIs have amplification 
of ERK2. Furthermore, MEK inhibitors effectively restored the sensitivity of EGFR 
TKIs. Similar to HER2 amplification, ERK2 amplification is mutually exclusive with 
T790M mutation [179]. 
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BRAF mutation: V600E and G469A, mutations in the BRAF, occur in 1 % of tumor 
samples that are resistant to TKIs.  Although the V600E mutation appears in patients with 
the EGFR T790M mutations, the G469A mutation is mutually exclusive [130]. 
JAK2: JAK proteins phosphorylate signal transducer and activator of transcription 
(STAT), which forms a homodimer that translocates into the nucleus where it binds to 
DNA and promotes transcription of genes. Studies have shown that JAK2 activation 
induces resistance to EGFR TKIs and that JAK 2 inhibitors restore the sensitivity to 
erlotinib in cellular and xenograft models [2, 68]. 
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1.2 Protein kinase C  
 
Protein kinase C (PKC) belongs to the AGC superfamily of kinases. On the basis 
of structural, functional and biochemical properties, PKC have been classified into three 
subgroups; conventional, novel and atypical. The conventional (cPKCs α, βI, βII and γ) 
are diacylglycerol (DAG) and phorbol ester sensitive and respond to Ca2+. The novel 
PKCs (nPKCs δ, ε, η and θ) only respond to phorbol esters or DAG. The atypical PKCs 
(aPKCs ι and ζ) are independent of DAG and Ca2+. cPKCs and nPKCs are activated in 
response to an increase in DAG levels in the plasma membrane. This increase could be 
triggered by activation of receptor tyrosine-kinases, which couple to phospholipase Cγ 
(PLCγ), or G-protein-coupled receptors (GPCRs) that couple with phospholipase Cβ 
(PLCβ). PLCs in turn hydrolyze phosphoinositide 4,5-biphosphate (PIP2) into second 
messengers inositol triphosphate (IP3) and DAG. Binding of DAG (or phorbol esters) 
occurs in the C1 domains located in the regulatory region. Additionally, the cPKCs have 
a C2 domain that is required for Ca2+ binding. In the case of the atypical PKCs, 
regulation is achieved through their N-terminal PB1 domain. Although DAG is an 
important lipid second messenger for PKC activation, PKC-mediated responses could 
also occur through protein modifications [66].  
At the membrane, PKCs undergo conformational changes that release the 
inhibition exerted by the pseudosubstrate sequence bound to the active site. In the open 
conformation, PKCs undergo a series of serine/threonine phosphorylations to achieve full 
activation. Phosphorylation in the activation loop at a TFCGT motif, conserved in many 
members of the AGC kinase superfamily, is required for full activation of PKCs. This 
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activation is catalyzed by phosphoinositide-dependent kinase 1 (PDK1) recruited by 
PIP3. Additional phosphorylations also occur at the C-terminal to lock the kinase domain 
in its active conformation [136]. At the plasma membrane, each PKC isozyme interacts 
with its anchoring protein, receptor of activated C-Kinase (RACK) and phosphorylates 
nearby substrates (Fig. 1.3) [121].  
  
 
Figure 1.3 Structure and activation of PKC isozymes 
cPKCs contain DAG responsive C1 domains and calcium binding C2 domains. The 
nPKC have C1 for the interaction with DAG but lack calcium binding C2 domains. 
Atypical PKCs are responsive neither to DAG nor to calcium. Upon increase in DAG 
(also calcium for cPKCs), PKCs localize to the plasma membrane where they interact 
with their specific anchoring protein, receptor for activated C-kinase (RACK) and 
phosphorylate nearby substrates leading to various cellular responses.   
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Protein kinase Cs in cancer development and progression 
 
PKC isozymes play important roles in the development and progression of many 
cancers by regulating cell cycle, survival, apoptosis, cell motility and malignant 
transformation. Although mutations and chromosomal rearrangements of PKC isozymes 
are rare events in cancer, altered expressions of PKCs have been associated with the 
development of many cancers including lung cancer (Table 1.2). PKCα, PKCβ, PKCδ, 
PKCε and PKCι have been implicated in lung cancer malignancy and the following 
section focuses on their roles in cancer progression.  
 
 Alpha Beta Delta Epsilon Iota 
Breast Assender, JW 
et al 2007 ↑; 
Kerfoot, C et 
al  2004 ↓ 
Gokmen-
Polar, Y et 
al 2010 ↑ 
 Pan, Q 
 et al 2005 ↑ 
Kojima, Y et 
al. 2008 ↑ 
Colon Suga, K et al 
1998 ↓ 
   Murray, NR et 
al. 2004 ↑ 
Lung   
 
 Bae, KM  
et al 2007 ↑ 
Regala, RP et 
al. 2005b ↑ 
Prostate  Metzger, E 
et al 2010 
↑ 
Kharait, S et 
al 2006 ↑; 
Villar et al 
2007↑ 
Aziz, et al 
2007 ↑; Koren, 
R et al , 2004 
↑; McJilton, 
MA et al, 2003 
↑ 
Ishiguro, H et 
al. 2009 ↑ 
 
 
Table 1.2 Altered expressions of PKC isozymes in primary tumor samples 
 
 
 
 
20 
 
PKC α: This PKC plays important roles in many cellular processes such as cell 
proliferation, cell cycle, apoptosis, and motility, and regulates the expression of genes 
associated with multidrug resistance. PKCα can act as a tumor suppressor or tumor 
promoter in different contexts. PKCα has been described as a pro-survival kinase in 
breast, endometrial, glioma and androgen-independent prostate cancer cells. These 
studies indicate that PKCα mediates mitogenic signals through the activation of the 
MAPK pathway, induction of CDK1 and inhibition of p21 [128, 171]. In contrast, 
PKCα is widely reported as a tumor suppressor in intestine and skin tumors. Analysis of 
tissue samples from PKCα-/- mice indicates higher expression of inhibitor of DNA 
binding (Id1) known for its tumorigenic properties in the crypts of the small intestine and 
colon tumors [141]. In skin cancer, PKCα overexpression suppresses tumor formation 
induced by the carcinogen DMBA. Similarly, PKCα has been shown to act as a tumor 
suppressor in KRAS-driven lung cancer models [73], and activation of PKCα in H358, 
H441 and H322 NSCLC cells in late G1/early S phase leads to senescence through up-
regulation of p21cip1 [133]. In contrast, a PKCα antisense oligonucleotide (ODN) 
exhibited additive antitumor effects on lung carcinomas, and depletion of PKCα in 
human lung carcinoma LTEP cells, significantly reduced tumor formation and size in 
nude mice underscoring the divergent role of PKCα in lung cancer cells [196].  
PKCα is ubiquitously expressed in human tissues, but exhibits altered expression 
in various cancer tissue samples [90]. A study on the role of PKCα in bladder cancer 
reported that tumor specimens have elevated levels of PKCα compared to normal bladder 
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tissue. Moreover, the levels of PKCα correlate with the malignant grade of the tumor 
samples [4]. There are controversial reports regarding the relationship between PKCα 
expression and advanced stages of breast cancer. Several clinical studies correlated 
overexpression of PKCα with advanced breast carcinoma and poor clinical outcomes of 
endocrine therapy. Tumor samples that have high staining for PKCα are negative for 
estrogen receptor expression. On the other hand, a clinical study involving 46 advanced 
stage breast cancer patients showed low PKCα staining in tumors compared to normal 
tissue [90]. In endometrial tumors, PKCα staining was variable among patients and 
different sections of tumors. Nevertheless, overall endometrial tumors express high 
PKCα levels relative to normal tissue [70]. Analysis of 30 tissue samples derived from 
human colorectal cancer patients indicated low expression of PKCα in tumor specimens 
[172].  Likewise, malignant renal cell carcinoma (RCC) tumors have much lower PKCα 
staining than benign oncocytomas [194] .  
By far the most consistent function of PKCα is its role in cell motility in different 
cancer types. PKCα has been implicated in migration of NSCLC cells in response to 
cytokines [31]. ErbB2-dependent activation of PKCα promotes cell invasion in breast 
cancer cells [183]. In glioma, the phorbol ester PMA enhances invasion and migration 
through activation of PKCα [105]. Activation of PKCα in response to various stimuli 
also induces invasion and migration in hepatocellular, melanoma, ovarian and 
endometrial cancer cells [22, 112, 197, 208].   
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PKCβ : PKCβI and PKCβII are the two splice variant of PKCβ derived from the same 
gene. PKCβ is mainly implicated in inflammation and angiogenesis but also plays roles 
in cell cycle, proliferation, differentiation and metastasis. The role of PKCβ is well 
reported in prostate, breast and colorectal cancers, as well as in lymphomas and 
glioblastomas. 
PKCβI is highly expressed in prostate cancer tumors compared to benign prostatic 
hyperplasias [116]. In the case of PKCβII, high levels are localized in endothelial cells 
leading to increased angiogenic capacity of prostate cancer cells. Furthermore, PKCβII 
controls cell proliferation and tumor growth. In vivo, tumor formation of PC3 cells was 
attenuated using a PKCβII specific inhibitor [64]. PKCβII protects chronic lymphocytic 
leukemia cells from apoptosis by regulating Bcl2 and Bim proteins. Phosphorylation of 
Bcl2 by PKCβ leads to inhibition of apoptosis by sequestering Bim. Moreover, high 
stromal PKCβII was found in patients with various hematological malignancies, which 
correlates with more aggressive stages of the disease. PKCβ is shown to regulate the 
activation of stromal NF-κΒ that results in the survival of leukemic B cells. In vivo, 
crossing T cell leukemia (TCL) transgenic mice that develop leukemia with PKCβ 
deficient mice abrogated the development of chronic lymphocytic leukemia (CLL) [111].  
In colon and breast carcinomas, the two splice variants have opposite roles. 
PKCβII enhances proliferation of intestinal epithelium and is required for the initiation of 
colon cancer [168]. Transgenic mice that overexpress PKCβII develop preneoplastic 
lesions and become susceptible to azoxymethane-induced colon carcinogenesis. The 
levels of colonic β-catenin were also elevated, accounting for proliferation due to 
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activation of the PKCβ/Wnt/APC/β-catenin pathway [125]. Furthermore, PKCβII 
promotes cell invasion through mechanisms that involve the RAS/MAPK and Rac1 
pathways. Spindler et al. reported that 18 % of primary colon adenocarcinomas exhibit 
very high levels of PKCβΙΙ, and high expression of PKCβII correlates with poor survival 
rates [168]. On the contrary, overexpression of PKCβΙ suppresses tumor formation of 
HT29 and SW480 colon cancer cells in xenograft models [61]. In breast cancer, 
overexpression of PKCβI suppresses proliferation, tumorigenic capacity, and metastasis 
while high levels of PKCβII are reported in several breast cancer cell lines and patient 
samples [101]. In murine cell lines derived from mammary tumors, overexpression of 
PKCβI leads to increased latency and slow growth of tumors in mice. Moreover, tumor 
cells that overexpress PKCβI have attenuated metastatic capacity to the lungs. On the 
other hand, PKCβII regulates VEGF-induced angiogenesis and growth in breast cancer 
cells. The expression levels of cytoplasmic PKCβII positively correlate with HER2 levels 
while nuclear PKCβII correlates positively with ER levels [60]. 
PKCβ reduces apoptotic signals and cell invasion in gastric and hepatocellular 
carcinomas. In hepatocellular carcinomas, PKCβII-mediated ERK/heat shock protein 27 
(HSP 27) activation is responsible for cell motility and invasion. Down-regulation of 
PKCβI expression and activity by a COX-2 specific inhibitor (SC-236) attenuates 
apoptotic response of gastric cancer cells [216]. Much of the studies on glioblastomas and 
lung cancer cells were done with the PKCβ specific inhibitor enzastaurin. In 
glioblastomas, PKCβ regulates proliferation by suppressing the activity of GSK3, S6 
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kinase and Akt. Moreover, the effect of the PKCβ inhibitor was shown using U87MG 
human glioblastoma cells inoculated in nude mice [185]. In NSCLC, treatment with 
enzastaurin inhibits the transcription of genes associated with tumor progression such as 
u-PAR and VEGF-C and up-regulates tumor suppressors. PKCβ inhibition in NSCLC 
cells also resulted in reduced migration, invasion and metastasis [204].  
PKCδ: PKCδ functions as a tumor suppressor as well as a pro-survival kinase in several 
cancer cell types. PKCδ activation depends on multiple factors such as proteolytic 
activation, tyrosine phosphorylation, intracellular localization, and the nature of apoptotic 
stimuli [11]. Studies have shown that activation of PKCδ inhibits cell cycle progression 
and down-regulation of PKCδ facilitates tumor formation. In lung cancer cells, 
overexpression of PKCδ led to PMA induced G1 arrest by regulating the expression of 
cell cycle inhibitor p21cipl [127, 156]. Suppression of p53 due to an increase in PKCδ 
expression was associated with colon cancer progression. The function of PKCδ as a pro-
apoptotic protein was further established by the observation that treatment with genotoxic 
agents results in cleavage of PKCδ by caspase-3 [149]. In androgen-dependent prostate 
cancer cells, PKCδ activation by PMA triggers the extrinsic apoptotic cascade through 
the activation of an autocrine loop that involves the secretion of the apoptotic factors 
TNFα and TRAIL. This pro-apoptotic cascade can be blocked with pharmacological 
agents against p38 MAPK and JNK, suggesting a role for MAPK cascade as effectors of 
the apoptotic response mediated by PKCδ [63]. Contrary to its role as a pro-apoptotic 
kinase, studies in breast, lung, pancreatic and liver tumor models have linked PKCδ to 
survival and enhanced resistance to anti-cancer drugs [11]. PKCδ specific inhibitors as 
25 
 
well as kinase-dead mutants were shown to attenuate cell survival in NSCLC and breast 
cancer cells. Moreover, PKCδ expression was found to be higher in estrogen receptor-
positive human breast tumors. Ectopic expression of PKCδ also enhanced anchorage-
independent growth and resistance to cytotoxic drugs in pancreatic and liver cancer cells 
[120]. Studies using genetically engineered mouse models also contribute to unravel roles 
of PKCδ in tumorigenesis. For example, PKCδ skin transgenic mice are resistant to 
tumor promotion by DMBA and PMA [145]. In lung cancer, KRAS-driven lung 
tumorigenesis was abrogated in PKCδ knockout mice [176]. Similarly, ErbB2 
overexpressing mice in a PKCδ−null background delays breast tumorigenesis [1].  
PKCδ is generally reported as a positive regulator of cell motility. In pancreatic 
and renal cell carcinoma, PKCδ phosphorylation led to enhanced cell motility [45, 120]. 
In glioma cells, PKCδ increased MMP-12 expression, which results in increased invasion 
[157]. Overexpression of claudin-1 activates a c-Abl-PKCδ signaling pathway, leading to 
a marked elevation in MMP-2 activity and invasion in human liver cancer cells [214]. 
The chemokine CCL5 induces the production of MMP-9 and an invasive phenotype in 
oral cancer cells also via a PKCδ-dependent mechanism [34]. In prostate cancer cells, 
PKCδ activation induces migration downstream of EGFR. Moreover, overexpression of 
PKCδ in prostate cancer cells enhances collagen secretion [193]. In gastric carcinoma 
cells, TGF-β-induced PKCδ expression enhances cell spreading, motility and invasion 
[32]. 
PKCε: This nPKC is overexpressed in many cancer types including skin, breast, lung, 
prostate, renal and head and neck squamous cell carcinoma. Overexpression of PKCε in 
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these cancers is associated with the development and progression of the disease. High 
PKCε staining in primary breast tumors correlates with a high histological grade, positive 
HER2 receptor status, and loss of hormone receptor [12]. Overexpression of PKCε has 
also been reported in greater than 90 % of NSCLC and prostate tumors [7]. 
PKCε functions as an anti-apoptotic kinase through its regulation of the cell cycle 
and expression of genes associated with cell survival. Studies have shown that 
PKCε promotes cyclin D1 induction leading to G1 to S phase progression during the cell 
cycle. Moreover, PKCε has been implicated in mitogenic signals through mechanisms 
that involve caspases, Bcl2 family members, the Raf/MEK/ERK pathway and other pro-
survival molecules [25, 26]. In NSCLC, PKCε protects cells against TRAIL-induced 
apoptosis and depletion of PKCε leads to enhanced expression of pro-apoptotic proteins. 
PKCε inhibition also attenuates tumor growth and metastatic dissemination in nude mice 
[25, 47]. In prostate cancer, PKCε depletion impairs the activation of the NF-κΒ pathway 
in response to TNFα. Moreover, overexpression of PKCε in normal immortalized 
prostate epithelial cells causes ERK and Akt activation and confers growth advantage. 
Prostate-specific overexpression of PKCε in mice led to the formation of preneoplastic 
lesions [18, 54]. Additionally, in androgen-dependent LNCaP cells, overexpression of 
PKCε results in tumor growth in nude mice. Similarly, overexpression of PKCε enhances 
tumorigenic and metastatic potential of breast cancer cells [108]. The role of PKCε in 
skin cancer initiation and progression has been shown using a skin-specific PKCε 
overexpressing transgenic mouse model. These mice exhibit phenotypic abnormalities 
27 
 
including inflammation, hyperkeratosis and ulceration resulting in a highly malignant and 
metastatic squamous skin cell carcinoma [203].  
PKCι: This aPKC is an oncogene required for maintenance of the transformed phenotype 
of NSCLC cells with KRAS mutations. Moreover, the PKCι-Par6-Rac1 signaling was 
found to be important for the transformation of NSCLC cells [50, 146].  PKCι also 
regulates the Rac1/Pak1/MEK/ERK signaling pathway involved in cell proliferation of 
NSCLC cells [147, 217]. Gene expression microarray analysis of U87MG glioma cells 
showed that PKCι suppressed the expression of RhoB, which has previously been 
reported to have a role in actin stress fiber formation [8]. In vitro and in vivo experiments 
also revealed the involvement of PKCι in prostate cancer cell growth through secretion of 
IL-6. Indeed, PKCι activates transcription of the IL-6 gene through NF-κΒ and AP-1, 
thus arguing for its involvement in hormone-independent prostate cancer cells [82]. PKCι 
is also a potential oncogene in ovarian cancer, as enhanced PKCι protein levels are 
associated with increased cyclin E protein expression and proliferation in ovarian cancers 
[217]. 
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1.3 Nuclear factor-κΒ  (NF-κΒ) transcription factors    
 
Nuclear factor-κB (NF-κΒ) represents a family of structurally related 
transcription factors that are implicated in various cellular processes including 
inflammation, proliferation, angiogenesis, transformation, apoptosis, invasion, and 
resistance to chemotherapy and radiation therapies. There are five members of the 
mammalian NF-κΒ family; RelA (p65), RelB, c-Rel, NF-κΒ1 (p50/p105) and NF-κΒ2 
(p52/p100). Each member contains a highly conserved 300 amino acid N-terminal region 
called Rel homology domain (RHD). This region comprises sub-domains for 
dimerization, nuclear localization (nuclear localization sequence, NLS) and DNA 
binding. The five members are further subdivided into two groups based on their catalytic 
activity. RelA, RelB and c-Rel contain  C-terminal transactivation domains, which are 
made up of serine and hydrophobic amino acids important for the transactivational 
activity. The RHD of RelA and c-Rel contains a phosphorylation site for Protein Kinase 
A (PKA) that is important for transcriptional activity. In the case of the NF-κΒ proteins 
p100 and p105, the C-terminal region consists of multiple copies of ankyrin repeats, 
which keeps the proteins in their inactive form. The NF-κΒ proteins are converted to 
active DNA-binding proteins (p105 to p50, and p100 to p52) by proteolytic cleavage or 
arrested translation, and as they lack the transactivation domain, they cannot act as 
activators of transcription except when they form dimers with the Rel proteins. NF-κΒ 
family members form multiple homo-and heterodimers depending on the cell type, nature 
of the stimulus, and the length of exposure. In general, p50/RelA or p52/RelA complexes 
are the most common dimers [13, 59].  
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NF-κΒ  activation pathways 
 
Activation of NF-κΒ occurs primarily by two signaling pathways; canonical and 
non-canonical pathways. Activation of the IκΒ kinase (IKK) complex is the common 
upstream regulatory step in both pathways of NF-κΒ activation. The IKK complex 
includes catalytic kinase subunits IKKα and IKKβ, and a regulatory subunit called NF-
κΒ essential modulator (NEMO). Although the signals mediated by IKKα and IKKβ 
differ, both could phosphorylate IκΒ and exhibit similar structural organization, including 
kinase domain, leucine zipper and helix-loop-helix domains with 52 % amino acid 
homology. IKKs become activated via phosphorylation of serine residues in the kinase 
domain (residues 176 and 180 in the case of IKKα and residues 177 and 181 in the case 
of IKKβ) by IKK kinases. The canonical pathway is activated in response to multiple 
stimuli, such as ligand binding to TNF receptors, IL-1 receptors, T-cell receptors, B-cell 
receptors, and Toll-like receptor 4 (TLR4). This pathway induces the transcription of 
genes implicated in inflammatory response, cell motility and growth [29, 59, 80]. 
Association of NF-κΒ dimers with their inhibitory proteins, inhibitors of NF-κΒ 
(IκB), sequesters the complex in the cytoplasm during the inactive state. The human IκΒ 
family of inhibitory proteins includes IκΒα, IκΒβ, IκΒγ, and IκΒε, which have different 
affinities for individual NF-κΒ dimers. IκΒs possess several ankyrin repeats, which are 
33 amino acid sequences that mediate binding to NF-kB dimers. Unprocessed NF-κΒ1 
(p105) and NF-κΒ2 (p100) also function as IκΒ proteins. IκΒ proteins sequester the NF-
κΒ dimers in the cytoplasm by hiding their nuclear localization sequences. With the 
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exception of IκΒβ, the expression of IκΒ proteins is regulated by NF-κΒ resulting in an 
autoregulatory loop of NF-κΒ signaling. The NF-κΒ/IκΒα complex is activated by 
phosphorylation on conserved serine residues in the N-terminal portion of IκΒ. This 
modification occurs at ser-32 and ser-36. Phosphorylation targets IκΒα for ubiquitination 
by the SCF-ubiquitin ligase complex, which leads to the degradation of the inhibitory 
subunit by the 26S proteasome. This process enables the p50/p65 dimer to translocate to 
the nucleus and bind to its DNA-binding site in the promoter or enhancer regions of 
specific genes. Several modifications of the p65 protein occur during active transcription 
of target genes. Phosphorylation of the p65 subunit by PKA or MAPKs at ser-276 is 
important for the recruitment of cAMP response element-binding (CREB) protein/p300 
[59]. Additionally, phosphorylation by casein kinase II and IKKs increases the 
transcriptional activity of NF-κΒ. Epigenetic modifications such as acetylation, 
methylation and demethylation of p65 also play a key role in the regulation of NF-κΒ 
transcriptional activity [28].  
In the case of the non-canonical pathway, activation of NF-κΒ is triggered by 
ligand binding to lymphotoxin β receptor, B-cell-activating factor, CD40, and CD30. 
Activation of the non-canonical pathway is involved in the development of lymphoid 
organs and the adaptive immune system. This pathway depends on the recruitment of 
TNF associated factor (TRAF) to the membrane and activation of IKKα by NF-κΒ 
inducing kinase (NIK). Activated IKKα forms a homodimer and phosphorylates p100, 
leading to its ubiquitination and generation of the p52 protein. p52 forms a heterodimer 
with RelB and localizes to the nucleus [59]. A third pathway that does not involve IKKs 
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has also been described for NF-κΒ activation. This atypical pathway includes DNA 
damage followed by activation of casein kinase 2 downstream of p38, resulting in 
phosphorylation and degradation of IκΒ (Figure 1.4) [175]. 
 
 
 
Figure 1.4 NF-κΒ  activation pathways 
 
In the canonical pathway, TNFα, IL-1β or LPS binds to their respective receptors and 
lead to IKK-mediated activation of IκΒα. IκΒα is degraded following activation and 
release p50/p65 to localize to the nucleus. In the non-canonical pathway, lymphotoxin β 
(LTβ) or B-cell activating factor (BAFF) are implicated in NF-κΒ inducing kinase 
(NIK)-mediated activation of IKKα. IKKα then phosphorylates p100, which then 
undergoes proteasomal processing to generate p52. RelB/p52 dimers are then released 
and translocate to the nucleus. The atypical pathway is triggered by DNA damage, which 
activates p38-induced casein kinase-2 (CK-2) and results in phosphorylation of IκΒα. 
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NF-κΒ  and cancer 
 
Dysregulation of the NF-κΒ signaling pathway is a common feature of many 
human diseases including cancer. NF-κΒ is important in integrating multiple stress 
stimuli and regulating innate and adaptive immune responses seen in inflammation, 
which is associated with or precede cancer initiation [15]. NF-κΒ activation occurs in 
premalignant cells that are destined to undergo malignant conversion as well as in cells 
that are recruited to the tumor microenvironment. These cells produce cytokines, 
angiogenic factors, and proteases that degrade the extracellular matrix to support cancer 
development and progression. The microenvironment cells include macrophages, 
dendritic cells, neutrophils, mast cells, T cells and B cells [13]. Generation of several 
inflammatory cytokines, including TNFα, IL-1β and IL-6, in some of these cells is 
known to be dependent on the canonical NF-κΒ pathway activation induced by 
inflammation. Secreted TNFα and IL-1β act on the premalignant cells to activate NF-κΒ, 
which induces expression of genes involved in inhibition of apoptosis and promotion of 
proliferation and angiogenesis. NF-κΒ activation in the microenvironment cells could 
also promote production of reactive oxygen species (ROS), which induce DNA damage 
of the premalignant cells. Such DNA damage activates NF-κΒ, which induces expression 
of anti-apoptotic genes to promote cancer progression [29, 59]. 
Various studies identified the role of NF-κΒ in both hematological and solid 
tumors. A viral homolog of c-Rel was shown to cause aggressive lymphomas and 
leukemias in chickens [27]. A wide variety of haematopoietic proliferations show 
dysregulated NF-κΒ signaling pathway including mutations in IκΒα, amplification of c-
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Rel, and chromosomal rearrangements in the NF-κΒ2 gene. In solid tumors, mutations of 
the NF-κΒ signaling pathway have been documented in breast and prostate cancers [178]. 
Studies have shown mutations in the NF-κΒ1, IKKβ as well as IκΒα and IκΒε as well as 
high levels of c-Rel in breast cancer [144]. A transgenic mouse that overexpressed c-Rel 
in the mammary gland developed one or more mammary tumors and had increased 
expression of NF-κΒ target genes, such as cyclin D1, c-myc and Bcl-XL [17]. In prostate 
cancer, gene fusion between IKKβ and transpoortin 1 resulted in elevated IKKβ 
expression [138]. Although RelA, RelB and NF-κΒ1 mutations are rare in other human 
cancers, these subunits are constitutively activated in a wide variety of human tumors. 
Increased RelA nuclear localization or activity is present in many tumors and is 
associated with tumor progression [74]. Gastric carcinoma shows increased nuclear 
translocation of RelA in comparison with adjacent normal epithelial cells and correlates 
with tumor invasion. NF-κΒ activation has also been identified in squamous cell 
carcinomas of the head and neck. Inhibition of NF-κΒ activity in these tumors attenuates 
cell survival and tumor growth[190]. The expression of IKKα has been correlated with 
increased expression of NF-κΒ and COX-2 in colorectal carcinomas. In vitro studies 
have also suggested a positive role for NF-κΒ in cell transformation in prostate and colon 
epithelial cells, fibroblasts, and lymphocytes [55, 195]. In lung cancer, tumor samples 
showed high levels of NF-κΒ activation associated with advanced stage of disease and 
poor prognosis. NF-κΒ activation in lung cancer has also been correlated with loss of p53 
function and KRAS mutation and mediates secretion of inflammatory cytokines that play 
an important role in lung cancer development [118].   
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PKC and NF-κΒ  in cancer  
 
The PKC family has long been known to play an important role in cell growth and 
differentiation by regulating the activity of transcriptions factors such as NF-κΒ. Phorbol 
esters can induce transient activation of NF-κΒ and control the expression of MMPs [75]. 
It has also been shown S6 kinase is responsible for phosphorylation of IκΒα at Ser-32 
after PMA stimulation [135]. Initial studies that link PKCs to NF-κΒ activation in cancer 
were reported for atypical PKCs. PKCζ phosphorylates and inactivates NF-κΒ upstream 
kinase, IKKβ at ser-177 and ser-181 in response to TNFα. Additionally the loss of PKCζ 
was shown to impair RelA phosphorylation and inhibit the translocation of NF-κΒ  to the 
nucleus. Deletion of PKCζ reduces NF-κΒ activation in lung in response to both TNFα 
and IL-1β [40, 124]. The other atypical PKC isozyme, PKCι also mediates 
phosphorylation of IKKβ in response to TNFα and induces NF-κΒ dependent 
transcription of the IL-6 in prostate cancer. Recently, our laboratory identified a key role 
of PKCε in TNFα dependent activation of NF-κΒ in prostate cancer. PKCε was shown to 
be a part of the TNFRI signaling complex that leads to NF-κΒ activation [54]. Yet 
another novel PKC isozyme, PKCδ was reported to facilitate RelA binding to the 
promoters of target genes in the nucleus [110]. Inhibition of both PKCδ and PKCε has 
been shown to prevent TNF-α-induced NF-κΒ activation, determined by NF-κΒ binding 
activity and IκΒα degradation in pancreatic cancer cells. Activation of the NF-κΒ 
pathway is also attributed, in part, to alterations in classical PKCs. PKCβ dependent 
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activation of NF-κΒ, through modulation of the IKK complex, was found to be crucial in 
the survival of chronic lymphocytic leukemia [111, 123]. For PKCα, the mechanism for 
it interactions with NF-κΒ was first shown using in vitro binding assays. PKCα forms a 
complex with NF-κΒ upstream kinase, IKK. Additionally PKCα have been shown to 
interact with IKKβ in response to PMA in 293T cells [135]. Mechanism for PKCα 
dependent NF-κΒ  activation was also extended to phosphorylation of RelA in glioma 
cells. In these cells, PKCα mediated activation of NF-κΒ results in pro-survival 
phenotype [126].  
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Overall goals and significance of research 
The goal of my thesis research has been to identify the association between PKC 
isozymes and different processes that contribute to lung cancer malignancy. Specifically, 
I focused on three different aspects: drug resistance, inflammation and tumorigenesis.  
First, I aimed to determine whether PKCs modulate erlotinib resistance in 
NSCLC. I used parental and derived erlotinib-resistant cell lines to profile PKC isozyme 
expression and study their roles in altering drug sensitivity and mesenchymal phenotype. 
The outcome of my study established PKCα and PKCδ as important regulator of erlotinib 
sensitivity. Moreover, high expression of PKCα was found to be important for the 
maintenance of the mesenchymal phenotype. Second, I wished to identify the 
requirement of PKCs for interleukin mediated NF-κΒ activation. I was able to show that 
activation of NF-κΒ in response to IL-1β is dependent on PKCα. These studies will 
contribute to establish PKCα specific inhibitors as combinational therapeutic options 
with indications of TKI resistance and NF-κΒ hyperactivation. 
Finally, based on previous findings from our lab implicating PKCε signaling to 
lung cancer progression, I aimed to identify whether its function also extends to 
tumorigenesis using animal models. I crossbred KRAS mutant mice with PKCε knockout 
mice, to study if PKCε modulates oncogenic driven tumor formation. In addition, I aimed 
to generate an inducible PKCε transgenic mouse model that could be used to study 
whether PKCε could by itself drive lung tumor formation. 
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Abstract 
Overexpression and mutational activation of the epidermal growth factor receptor 
(EGFR) plays an important role in the pathogenesis of non-small-cell lung cancer 
(NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are given as a primary therapy for 
patients with EGFR activating mutations; however, the majority of these patients 
eventually develop resistance to TKIs. To address a potential role of PKC isozymes in the 
resistance to TKIs we used an isogenic model: the NSCLC H1650 cell line and its 
erlotinib-resistance derivative H1650-M3. H1650-M3 cells display a mesenchymal-like 
morphology driven by TGFβ signaling [212]. We found that H1650-M3 cells display 
remarkably high levels of PKCα and reduced levels of PKCδ. Notably, RNAi depletion 
of PKCα from H1650-M3 cells caused a significant reduction in the expression of EMT 
markers vimentin, Zeb2, Snail and Twist. Moreover, pharmacological inhibition or 
silencing of PKCα sensitized H1650-M3 cells to erlotinib. Whereas ectopic 
overexpression of PKCα in parental H1650 cells did not alter the expression of EMT 
genes or confers resistance to erlotinib, it resulted in down-regulation of PKCδ 
expression. Forced PKCδ overexpression in H1650-M3 cells also sensitizes the resistant 
cells to erlotinib. In addition, we observed that treatment of H1650-M3 cells with the 
TGF-β inhibitor LY2109761 attenuates the expression of PKCα. Moreover, PKCα 
overexpression cooperates with TGF-β for the induction of specific EMT markers. Our 
results highlight a potential role for PKCs in EMT and erlotinib resistance in lung cancer 
cells, and suggest a potential therapeutic role for PKCα inhibition in lung cancer 
treatment. 
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2.1 Introduction  
 
Lung cancer remains one of the major causes of mortality worldwide, accounting 
for more deaths than any other cancer cause. Diagnosis of lung cancer normally occurs in 
late stages of the disease process, thus limiting the options for treatment. The most 
common type of lung cancer (~85 %) is non-small cell lung cancer (NSCLC), which 
includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [24, 162]. 
Genetic alterations in NSCLC tumors have been extensively studied, and include 
primarily oncogenic mutations in epidermal growth factor receptor (EGFR) and KRAS, 
as well as inactivation of tumor suppressor genes such as p53, PTEN, Rb, and p16 [77, 
86, 148]. Mutations in EGFR, particularly deletion of exon 19 and L858R mutation in 
exon 21 occur in 10-50% NSCLC patients depending on the population studied [36, 56]. 
Small molecule tyrosine kinase inhibitors (TKIs) that reversibly inhibit EGFR at the ATP 
pocket domain, such as erlotinib and gefitinib, currently represent the first-line 
therapeutic option for EGFR-mutated NSCLC patients [3]. Although these therapies are 
initially efficacious, ultimately most patients develop resistance. Whereas resistance has 
been attributed in some cases to the acquisition of mutations in EGFR (such as the 
T790M mutation) or MET amplification [44, 94], the mechanisms behind the resistance 
to TKIs have not been fully evaluated. A deep understanding of the signaling 
mechanisms driving resistance is crucial for designing combinational therapy regimes to 
overcome this hurdle and extend life expectancy of NSCLC patients. 
Protein kinase C (PKC) represents group of serine-threonine kinases involved in a 
variety of cellular functions, including mitogenesis, survival, and motility.  This family of 
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kinases is composed of 11 members classified into three classes based on their 
biochemical and structural properties: calcium-dependent or conventional PKCs (cPKCα, 
βI, βII, and γ), calcium-independent or novel PKCs (nPKCδ, ε, η, and θ), and phorbol 
ester/diacylgycerol (DAG) unresponsive or atypical PKCs (aPKCsζ and ι/λ) [66]. 
Decades of research have established key roles for different members of the PKC family 
in the progression of cancer [53, 66]. Individual PKC isozymes can either act as tumor 
promoters or tumor suppressors in various cancers including lung cancer. For example, 
PKCβ has been proposed to be involved in lung tumorigenesis, and the PKCβ inhibitor 
enzastaurin has been studied as a potential anti-cancer agent for lung cancer patients 
[186, 204]. Our laboratory recently showed that PKCε, a kinase implicated in cell cycle 
progression and motility of NSCLC cells, is required for the tumorigenic and metastatic 
activities of NSCLC cells [25, 26]. On the other hand, PKCα and PKCδ negatively 
modulate NSCLC cell cycle progression. Most recently, Hill et al. provided direct 
evidence for a tumor suppressive role of PKCα in KRAS driven tumorigenesis [73]. 
Other reports on the contrary indicate that PKCα promotes NSCLC cell migration [31] 
arguing for divergent roles for this kinase in lung cancer progression. Likewise, diverse 
roles for PKCα and other members of the PKC family have been established in cell 
survival in NSCLC and other cancer types. 
Towards the goal of determining a potential role of PKC isozymes in TKI 
resistance in lung cancer, here we took advantage of an isogenic NSCLC cell model of 
erlotinib-resistance generated by culturing the parental H1650 cell line in the presence of 
a high concentration of the TKI. Erlotinib-resistant cells were shown to display features 
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of epithelial-to-mesenchymal transition (EMT), a phenotype that was found to be 
maintained by the transforming growth factor beta (TGF-β) pathway [212]. Our study 
identified discrete roles for PKC isozymes in erlotinib resistance and EMT in NSCLC 
cells.  
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2.2 Results 
 
Erlotinib-resistant cells display altered expression of PKC isozymes 
Changes in the expression levels of PKC isozymes have been associated with the 
progression of many types of cancers, including lung cancer [53]. In order to determine a 
potential involvement of PKC isozymes in erlotinib resistance, we took advantage of an 
isogenic NSCLC cell model; the parental H1650 cell line and its erlotinib-resistant 
derivative H1650-M3 [212]. H1650 cells express the conventional PKCα, novel PKCδ 
and PKCε, and atypical PKCs. Western blot analysis shown in Fig. 2.1A revealed a 
remarkable up-regulation of PKCα in the erlotinib-resistant variant H1650-M3. H1650-
M3 cells also have reduced PKCδ levels. Determination of mRNA levels for these two 
PKCs led to similar conclusions. Indeed, H1650-M3 cells have 25-fold higher PKCα 
mRNA levels than the parental H1650 cells, whereas PKCδ mRNA levels are reduced by 
5-fold in the erlotinib-resistant cell line (Fig. 2.1B). 
 
PKCα  is required but not sufficient to induce erlotinib resistance 
To assess a potential association between altered PKCα expression and erlotinib-
resistance, we used both pharmacological and RNAi approaches. As PKCα has been 
implicated in drug resistance in some cancer types [30, 99, 220] and its levels are 
strikingly high in erlotinib-resistant cells, we speculated that this PKC is involved in 
acquired resistance to erlotinib in NSCLC cells.  
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Figure 2.1. Erlotinib-resistant cells are characterized by altered expressions of PKC 
isozymes  
 
(A) Expression of PKC Isozymes was analyzed in parental (H1650) and erlotinib-
resistant (H1650-M3) cells. Protein levels of PKCs were determined by Western blot. (B) 
mRNA levels of PKCα and PKCδ were measured using real-time quantitative PCR in 
H1650 and H1650-M3 cells. Human 18S rRNA was used as an endogenous control. 
Fold-changes in mRNA levels were determined by normalizing to mRNA levels in 
H1650 using the ΔCt method. **, p < 0.01; ***, p < 0.001 
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In initial experiments (Fig. 2.2A), we observed that treatment of H1650-M3 cells with the 
pan PKC inhibitor GF 1090203X (5 µM, added 1 h before and during erlotinib treatment) 
increases the sensitivity of H1650-M3 cells to erlotinib (10 µM). Next, we examined the 
action of Gö6976, which preferentially inhibits cPKCs. As shown in Fig. 2.2B, Gö6976 
(5µM) also enhances the killing effect of erlotinib in H1650-M3 cells. As PKCα is the 
only cPKC expressed in these NSCLC cells, these results suggest the possibility that 
PKCα mediates erlotinib resistance. 
To unambiguously establish a role for PKCα in erlotinib resistance, we used 
RNAi. Two different PKCα RNAi duplexes, were transfected into H1650-M3 cells, 
which deplete PKCα by > 90 % upon delivery into H1650-M3 cells relative to a non-
target control RNAi duplex (Fig. 2.2C, inset). A dose-response analysis for inhibition of 
cell viability by erlotinib treatment established an IC50 = 5.1 ± 0.8 µM (n=3) in control 
H1650 cells (which is similar to parental H1650 cells, [212] and data not shown). On the 
other hand, IC50 in H1650-M3 cells was > 20 µM (n=3), as determined in a previous 
study [212]. Notably, PKCα depletion sensitizes H1650-M3 cells to erlotinib, as 
determined by the reduction in IC50 (8.7 ± 1.4 µM, for PKCα #1 RNAi; 9.2 ± 3.0 µM, for 
PKCα #2 RNAi) (Fig. 2C). To determine if PKCα up-regulation plays a role in inducing 
erlotinib resistance, we overexpressed PKCα in parental H1650 cells using an adenovirus 
(Adv). A LacZ Adv was used as control (Fig. 2.2D, inset). We found that PKCα 
overexpression failed to alter the response of H1650 cells to erlotinib (IC50 = 4.7.± 1.3 
µM, for PKCα AdV; IC50 = 5.5 ± 2.0 µM, for LacZ Adv). Thus, our data indicate that 
45 
 
although PKCα is required for the resistance of NSCLC cells to erlotinib, overexpression 
of this kinase is not alone sufficient to induce erlotinib resistance. 
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Figure 2.2 PKCα  protects H1650-M3 cells from erlotinib induced cell death 
 
(A) Erlotinib-resistant (H1650-M3) cells were pre-treated for 1 h with vehicle or the pan-
PKC inhibitor GF109203X (5 µM). Cells were then treated with erlotinib (10 µM), and 
cell viability was determined 24 h later using MTS. **, p<0.01. (B) Erlotinib-resistant 
(H1650-M3) cells were pre-treated for 1 h with vehicle or a classical PKC inhibitor 
Gö6976 (5 µM). Cells were then treated with erlotinib (10 µM), and cell viability was 
determined 24 h later using MTS. *** p<0.001. (C) Parental H1650 and erlotinib-
resistant (H1650-M3) cells were seeded in 96-well plates. H1650-M3 cells were 
transfected with either PKCα RNAi duplexes (α1 or α2) or non-target control (NTC). 
After 48 h, cells were treated with erlotinib at the indicated concentrations. Cell viability 
was determined 24 h later using MTS. (D) H1650 cells were infected with either LacZ 
Adv or PKCα Adv (30 MOI). 5 days following infection, H1650-PKCα were seeded in 
96-well plates and treated with erlotinib at the indicated concentrations the following day. 
Cell viability was determined 24 h later using MTS. 
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PKCδ  alters the sensitivity of H1650-M3 cells to erlotinib 
Our results clearly ascribe a role for PKCα in determining the sensitivity of 
H1650 cells to erlotinib. The fact that H1650-M3 cells display PKCδ down-regulation 
relative to parental cells prompted us to investigate whether changes in PKCδ levels 
could also dictate the sensitivity to the TKI. It has been reported that PKCδ mediates 
cytotoxic effect of several anti-cancer drugs [81, 221]. To address this issue, we 
overexpressed PKCδ in H1650-M3 cells using a PKCδ Adv. A LacZ Adv was used as a 
control (Fig. 2.3A). As shown in Fig. 2.3B, overexpression of PKCδ in erlotinib-resistant 
cells caused a reduction in the IC50 for erlotinib. The effect was proportional to the 
expression levels of PKCδ obtained by infecting cells with different MOIs of the 
PKCδ AdV. Indeed, infection with an MOI=1 pfu/cell did not cause any significant 
PKCδ overexpression and consequently failed to sensitize H1650-M3 cells to erlotinib 
(IC50 = 24.2 ± 0.6 µM for PKCδ Adv; IC50 = 24.7 ± 2.0 µM for LacZ Adv). On the other 
hand, an MOI=10 pfu/cell caused a noticeable shift to the left in viability dose-response 
for the erlotinib (IC50 = 8.7± 1.9 µM for PKCδ Adv; IC50 = 26.4 ±0.4 µM for LacZ Adv). 
At higher MOIs, the sensitivity of H1650-M3 cells was essentially similar to that 
observed in control (LacZ-infected) H1650 cells (MOI=30: IC50 = 6.3 ± 0.5 µM for 
PKCδ Adv; IC50 = 22.2 ± 0.4 µM for LacZ Adv; MOI=100: IC50 = 4.5 ± 0.4 µM for 
PKCδ Adv; IC50 = 19.5 ± 1.0 µM for LacZ Adv. These results indicate that PKCδ down-
regulation contributes to erlotinib resistance of NSCLC cells. 
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Previous studies have shown that overexpression of one PKC isozyme could alter 
the expression PKC family member. For example, overexpression of PKCα could alter 
the expression of PKCδ, PKCε and PKCι in different cellular models [107, 154, 198]. As 
erlotinib-resistant H1650 cells display PKCα overexpression and PKCδ down-regulation 
relative to the parental cell line, we asked if there was a mutual regulation controlling 
these changes. To test our hypothesis, we either overexpressed PKCα or depleted PKCδ 
in in the parental H1650 cells.  
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Figure 2.3 PKCδ  alters the sensitivity of H1650-M3 cells to erlotinib 
 
(A) Overexpression of PKCδ after 5 days was confirmed using Western blot. (B) H1650-
M3 cells were infected with either LacZ Adv or PKCδ Adv at different MOI. 48 h after 
infection, H1650-M3-PKCδ cells were seeded in 96-well plates, and treated with 
erlotinib at indicated concentrations 24 h later. Cell viability was determined the 
following day using MTS. 
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Interestingly PKCα overexpression by adenoviral means reduced the expression 
of PKCδ mRNA and protein levels. These effects were proportional to the levels of 
PKCα overexpression achieved by using increased MOIs of the PKCα Adv (Fig. 2.4A 
and 2.4B). In the next set of experiments we assessed if down-regulation of PKCδ alters 
PKCα expression levels. PKCδ expression was silenced from parental H1650 cells using 
RNAi and PKCα levels were determined by Western blot. As shown in Fig. 2.4C, both 
control and PKCδ silenced H1650 cells display similar PKCα levels. Furthermore, we 
overexpressed PKCδ in erlotinib-resistant M3-H1650 cells, and expression levels of 
PKCα essentially remain unchanged (Fig. 2.4D). These results argue for a unidirectional 
cross-talk between PKCs whereby overexpression of PKCα in NSCLC cells contributed 
to the down-regulation of PKCδ, but PKCδ levels were unable to influence those of 
PKCα. 
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Figure 2.4 PKCα  modulates the expression of PKCδ   
 
(A) H1650 cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at 
different MOI. Changes in PKCα, and PKCδ mRNA were determined by qPCR 72 h 
after infection. Results are expressed as fold-change relative to LacZ Adv. (B) Protein 
levels of PKCα and PKCδ were analyzed by Western blot 72 h after infection. (C) 
Parental H1650 cells were transfected with either PKCδ RNAi dupleses (δ1 or δ2) or 
non-target control (NTC) RNAi duplexes. Expression of PKCα and PKCδ were analyzed 
by Western blot after 72 h. (D) H1650-M3 cells were infected with either LacZ Adv or 
PKCδ Adv (100 MOI). The expressions of PKCδ and PKCα were measured in H1650, 
H1650-M3 and PKCδ overexpressing H1650-M3 cells after 96 h using Western blot. 
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PKCα  is required for the maintenance of H1650-M3 cell mesenchymal phenotype 
 Erlotinib-resistant H1650 cells exhibit mesenchymal properties, a phenotype that 
is mediated by TGF-β [212]. The mesenchymal phenotype is a hallmark of cancer stem 
cells exhibiting aggressive phenotype [182]. A recent study in breast cancer showed that 
PKCα is up-regulated in cells that had undergone EMT [181], thus we speculated that 
this kinase might contribute to the maintenance of the mesenchymal phenotype of 
erlotinib-resistant cells. Parental H1650 cells were sorted into CD44high/CD24low and 
CD44low/CD24high enriched populations, and PKCα mRNA levels were determined in 
both populations using qPCR. This experiment shows that PKCα mRNA levels were 
elevated in the CD44high/CD24low cells (Fig. 2.5A).  
As shown in a previous study [212], H1650-M3 cells display markedly elevated 
levels of genes associated with EMT, including vimentin, Snail, Twist, and Zeb as well as 
reduced levels of E-cadherin. To establish a potential involvement of PKCα up-
regulation in the mesenchymal phenotype of H1650-M3 cells, we examined the 
expression of EMT markers after silencing PKCα. Notably, PKCα RNAi depletion 
markedly reduced vimentin, Snail, Twist, and Zeb levels, suggesting that this kinase 
mediates the induction of these EMT genes. Levels of the epithelial marker E-cadherin 
remained unaffected (Fig. 2.5B). For those markers that could be readily detected by 
Western blot (vimentin and Snail), changes were also validated at the protein level (Fig. 
2.5C). Despite the PKCα requirement for the expression of EMT markers, it became 
apparent that overexpression of this kinase in the parental H1650 cells was not sufficient 
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to induce these EMT genes, as determined by qPCR 72 h after infection with increased 
MOIs of the PKCα Adv (Fig. 2.5D). No changes were observed even 1 week after PKCα 
Adv infection. Altogether, these results indicate that PKCα is required for the 
maintenance of mesenchymal phenotype of erlotinib-resistant cells, however its 
overexpression is insufficient to induce this phenotypic change.  
Next, we set to explore whether PKCδ has a role in the expression of genes 
associated with EMT transition. As PKCδ is down-regulated in H1650-M3 cells, we 
adenovirally overexpressed PKCδ in these cells and assessed the expression of EMT 
markers by qPCR. Unlike PKCα silencing, ectopic overexpression of PKCδ in H1650-
M3 cells did not change the expression of vimentin, Twist, or Zeb2, although a reduction 
in Snail levels could be observed. Likewise, PKCδ overexpression did not affect E-
cadherin mRNA levels (Fig. 2.5E). Consistent with these results, no changes in protein 
levels for E-cadherin and vimentin could be observed (Fig. 2.5F). We also found that 
PKCδ RNAi depletion from parental H1650 cells failed to change the expression of EMT 
markers (Fig. 2.5G). Therefore, the involvement of PKCδ is only confined to erlotinib 
resistance but not to EMT. 
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Figure 2.5 PKCα  is required but not sufficient for maintenance of mesenchymal 
phenotype 
 
 (A) Parental H1650 cells were analyzed by flow cytometry for CD44 and CD24 
expressions. Following the analysis, cells were sorted into CD44high/CD24low and 
CD44low/CD24high sub-populations and the levels of PKCα and PKCδ mRNA were 
compared by qPCR in each population. (B) H1650-M3 cells were transfected with either 
PKCα RNAi (α1 or α2) or non-target control (NTC) RNAi duplexes. After 72 h, RNA 
was extracted for qPCR analysis of selected genes associated with epithelial or 
mesenchymal phenotypes. Results are expressed as fold-change relative to parental 
H1650 cells. (C) Proteins were extracted after PKCα RNAi depletion and levels of 
epithelial and mesenchymal markers were determined using Western blot. (D) H1650 
cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at different MOI.  
After a week, expression mesenchymal genes and E-cadherin were determined using 
qPCR. (E) H1650-M3 cells were infected with either LacZ Adv or PKCδ Adv (100 
MOI). After 96 h, the mRNA level of mesenchymal associated genes was measured. (F) 
Western blot showing the protein expression of PKCδ, Vimentin and E-cadherin. (G) 
Parental H1650 cells were transfected with either PKCδ RNAi (δ1 or δ2) or non-target 
control (NTC) RNAi duplexes. Expression of PKCδ, E-cadherin and Snail were analyzed 
by Western blot after 72 h. 
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PKCα  up-regulation in erlotinib-resistant cells is mediated by TGF-β  
TGF-β has been widely implicated in EMT in multiple cancer types [35, 88, 201]. 
Activation of the TGF-β signaling pathway mediates EMT and erlotinib resistance in 
H1650 cells [212]. Based on this premise, we sought to establish if a causal relationship 
exists between TGF-β signaling and PKCα expression. H1650-M3 cells were treated 
with the TGF-β inhibitor LY2109761 for different times, and its efficacy to inhibit TGF-
β signaling was confirmed by its ability to reduce Smad2 phosphorylation (data not 
shown). Notably, the TGF-β inhibitor caused a time dependent reduction in PKCα 
mRNA levels (Fig. 2.6A). This effect was noticeable at the protein level particularly 48 
and 72 h after LY2109761 treatment (Fig. 2.6B). Furthermore, we treated parental H1650 
cells with recombinant TGF-β for different times, and found that it caused a significant 
PKCα up-regulation both at mRNA and protein levels. This effect was quiet remarkable 
after long term treatment with TGF-β (Fig. 2.6C and 2.6D). Therefore, TGF-β signaling 
is implicated in the overexpression of PKCα in erlotinib-resistant cells. 
Lastly, we sought to establish an association between PKCα up-regulation and 
TGF-β signaling in the induction of the mesenchymal phenotype. H1650 cells were 
infected with the PKCα Adv (or LacZ Adv as a control) and then subject to TGF-β 
treatment. mRNA was extracted a week after treatment and EMT markers were 
determined by qPCR. As shown in Fig. 2.6E, overexpression of PKCα potentiated the 
induction of the mesenchymal genes vimentin, Snail and Twist, by TGF-β .   
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Figure 2.6 TGF-β  signaling controls expression of PKCα  in erlotinib-resistant cells 
 
(A) Erlotinib-resistant (H1650-M3) cells were plated overnight and treated with a TGF-β 
inhibitor (LY2109761, 5 µM) for the indicated times. PKCα mRNA levels were 
measured by qPCR. (B) Protein levels of PKCα were determined by Western blot and 
densitometric analysis was carried out as described before. (C) Parental H1650 cells were 
cultured on a 60 mm plate and treated with TGF-β (5 ηg/ml) for 24 h, 48 h, 1 week or 2 
weeks.  PKCα protein levels were determined using Western blot. (D) mRNA levels of 
PKCα were determined after 6 h and 2 weeks of TGF-β treatment.  (E) H1650 cells were 
infected with either LacZ Adv or PKCα Adv (30 MOI).  24 h after infection, H1650-
PKCα cells were treated with TGF-β (5 ηg/ml) for a week. mRNA expressions for 
PKCα and genes associated with epithelial and mesenchymal phenotypes were assessed 
using qPCR. 
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2.3 Discussion 
 
Tumors harboring activating mutations of EGFR depend on the oncogene to 
maintain their malignant proliferation and survival. TKIs such as erlotinib have been 
effective for treatment of NSCLC patients with EGFR activating mutations. However, 
many of the patients exposed to erlotinib develop acquired drug resistance to the 
targeted-molecular therapy. One of the main causes of drug resistance is a relief of EGFR 
addiction and dependence on other oncogenic alterations. Characterization of signaling 
pathways implicated in the new oncogenic alteration is important to determine an 
effective therapy for patients with acquired resistance. PKC isozymes have been 
recognized as key effectors of known oncogenes such as c-MET, KRAS and TGF-β, 
which are implicated in induction of drug resistance [14, 21, 132]. Moreover, phorbol 
esters, which are known activators of PKCs, have been shown to induce multidrug 
resistance in cellular and xenografts models. In this regard, early studies in breast and 
small cell lung cancer have identified a role of phorbol esters in inducing phosphorylation 
of drug efflux pumps leading to reduced drug accumulation [48]. 
Here we present evidence for the role of PKC isozymes in the mechanisms of 
erlotinib resistance and epithelial-mesenchymal transition in NSCLC cells. Using 
isogenic cell models, we found correlations between alteration in PKC isozymes 
expressions and induction of resistance to erlotinib. Indeed, erlotinib-resistant H1650-M3 
cells exhibit high levels of PKCα while PKCδ expression was down-regulated. Although 
this is the first evidence for the involvement of the two PKC isozymes in resistance to 
molecular-targeted therapy, altered expressions of PKCα and PKCδ have been detected 
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in several cancer cells resistant to endocrine therapy and chemotherapeutic drugs. 
Elevation of PKCα expression or activity has been reported in pancreatic, colon, glioma 
and gastric cancer cells resistant to chemotherapeutic drugs such as cisplatin, doxorubicin 
and vincristine [30, 114, 207, 220] Interestingly, comparable to what is observed in 
erlotinib-resistant cells, continuous exposure of MCF-7 cells to Tamoxifen rendered high 
levels of PKCα and down-regulation of PKCδ [102]. 
Studies have indicated the importance of PKCα overexpression in protecting 
cancer cells against drug-induced cell death. PKCα overexpression in colon cancer cells 
attenuated doxorubicin induced apoptosis by elevating phosphorylation of Bcl-2, Bad and 
decreasing PARP cleavage PKCα has also been shown to regulate the cell cycle kinase 
cyclin D in drug resistant pancreatic cancer cells. More importantly, in several drug 
resistant cancer models, PKCα overexpression has been associated with reduced drug 
resistance by inducing increased expression and phosphorylation of a drug efflux pump, 
P-gp, encoded by the multidrug resistant gene 1 (MDR1) [99].  The functional importance 
of PKCα overexpression has further been demonstrated by using pharmacological 
inhibitors and RNA interference. Inhibition of PKCα using Gö6976 restored the 
sensitivity of pancreatic cancer cells to chemotherapeutic drugs [30]. Blocking PKCα by 
RNAi interference also reversed drug resistance in ovarian cancer cells [220]. In our 
study, we found that RNAi depletion or inhibition of PKCα using Gö6976 sensitize 
erlotinib-resistant NSCLC cells to the TKI.  
Overexpression of one PKC isozyme could lead to altered expression of other 
members of the PKC family and there are several potential reasons suggested for the 
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observed phenomenon. Overexpression of one PKC isozyme could compete for 
proteases, which are required for degradation of other PKCs. Alternatively cross-
phosphorylation between PKCs, could change the sensitivity to proteolysis and result in 
mRNA stability [154]. In other cases, the alteration in more than one PKC isozymes 
occurs as cross-regulation by several PKCs is required to achieve a full transformed 
phenotype. For example, as shown in MCF-7 cells, overexpression of PKCα resulted in 
down-regulation of endogenous PKCδ and reduction in PKCδ expression as well as high 
levels of PKCα were found to be important for the phenotypic changes observed in 
MCF-7-PKCα cells [198]. Similar phenomenon was observed in the H1650 where 
overexpression of PKCα resulted in down-regulation of PKCδ comparable to the levels 
in erlotinib-resistant H1650-M3 cells. Moreover, we found that the overexpression of 
PKCα as well as down-regulation of PKCδ were important to maintain erlotinib 
resistance in H1650-M3 cells. 
As previously characterized, H1650-M3 cells have elevated expression of genes 
associated with EMT and display morphological changes that are reminiscent of 
mesenchymal phenotype. Interestingly, the parental erlotinib naive cells were shown to 
possess a subpopulation of cells that are mesenchymal, erlotinib-resistant and similar to 
H1650-M3 cells [212], indicating that H1560-M3 cells were potentially generated 
through a selection process that favors the survival of cells that utilize alternate 
mechanisms to overcome drug-induced death. Certainly the identification of these 
mechanisms is crucial to effectively target drug-resistant tumors. PKCα has been 
implicated in the survival of cancer stem cells, which are known to arise during EMT 
64 
 
[181]. Inhibition of PKCα was shown to preferentially induce apoptosis of breast cancer 
stem cells. Additionally, elevated PKCα expression was found in a subpopulation of 
normal mammary epithelial cells enriched with a mesenchymal surface marker CD44 
[181]. Similarly, our results indicate a correlation between enrichment of mesenchymal 
phenotype and PKCα expression. Inhibition of PKCα in H1650-M3 cells also led to 
inhibition of genes associated with mesenchymal phenotype. Interestingly, although 
exposure to erlotinib resulted in differential expression of EMT markers including up-
regulation of mesenchymal genes such as vimentin, snail, twist and Zeb2, and 
downregulation of the epithelial marker E-cadherin, the effect of inhibiting PKCα was 
limited to the genes associated with mesenchymal phenotype underscoring its role in the 
maintenance of this phenotype.  
Several factors could regulate the expression of PKCα in NSCLC cells. As TGF-
β signaling was shown to be sufficient and required for the induction of erlotinib 
resistance and EMT in H1650-M3 cells [212], we explored a potential relationship 
between TGF-β and PKCα. Inhibition of TGF-β signaling blocked the expression of 
PKCα in H1650-M3 cells. Moreover, treatment with TGF-β increased the expression of 
PKCα in the parental erlotinib sensitive epithelial cells indicating that in the process of 
acquiring an aggressive phenotype, TGF-β up-regulated the expression of PKCα. 
Although the promoter region of PKCα does not consist of a TGF-β binding region, 
studies have identified PKCα as a TGF-β target gene. For example, gene profiling in 
A549 lung adenocarcinoma cell lines has shown that Prkca is one of the genes up-
regulated by TGF-β treatment [142]. In conclusion our results provide evidence for a role 
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of PKCs in acquired resistance and EMT and suggest a potential use of PKCα inhibitors 
to specifically target mesenchymal tumors including cancer stem cells that are resistant to 
therapy. 
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2.4 Materials and Methods 
 
Reagents 
Erlotinib hydrolchloride was purchased from Santa Cruz (Santa Cruz, CA). The 
pan-PKC inhibitor GF109203X was purchased from Enzo Life Sciences (Plymouth 
Meeting, PA). The cPKC inhibitor Gö6976 was obtained from LC laboratories (Woburn, 
MA). The CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was 
purchased from Promega. 
 
Cell Culture 
H1650 and H1650-M3 cell lines were generated in the laboratory of Dr. Raffaella 
Sordella (Cold Springs Harbor, NY) [212] and cultured in RPMI 1640 medium 
supplemented with 5 % FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells 
were maintained at 37 °C in a humidified 5 % CO2 atmosphere. 
 
Real-time PCR 
Total RNA was extracted from subconfluent cell cultures using RNeasy Kit from 
Qiagen (Valencia, CA). Total RNA (1 µg) was reverse transcribed to cDNA using 
Taqman reverse transcription reagent kit in a total volume of 20 µl (Applied Biosystems, 
Branchburg, NJ).  Real-time quantitative PCR (qPCR) was performed using an ABI 
PRISM 7700 detection system. The reaction was carried out in triplicate containing 
TaqMan universal PCR MasterMix (Applied Biosystems), target primers (300 nM), 
fluorescent probe (200 nM), and 4 µl of transcribed cDNA (6X dilution). Taqman 
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primers 5’end-labeled with 6-carboxyfluorescein (FAM) for PKCα, PKCδ, E-cadherin, 
Snail, Twist1, Vimentin, Zeb2 and 18S rRNA (housekeeping gene) were used. PCR 
product amplification was continuously monitored using the sequence detection system 
software version 1.7 (Applied Biosystems). Triplicate circle threshold (Ct) values were 
averaged and normalized to an average 18S Ct value to calculate the ΔCt. The Δ (ΔCt) 
was determined by subtracting the control ΔCt value from the experimental ΔCt value. 
Fold change were expressed as 2-ΔΔCt.  
 
Western blot 
Cells were harvested in lysis buffer (125 mM Tris-HCl, pH 6.8, 50% glycerol, 4% 
SDS, 0.08% bromophenol blue, and 20 % β-mercaptoethanol). Samples were resolved in 
10 % SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, 
Bedford, MD). After blocking with 5 % milk in 1 % Tween 20/PBS, membranes were 
incubated with the primary antibody. The following primary antibodies were used: anti-
PKCα (EMD Millipore Corp., Billerica, MA), anti-PKCε (Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-PKCι (Abcam, Cambridge, MA), anti-PKCδ, anti-vimentin, anti-
E-cadherin, anti-Snail, anti-phospho-Smad2 (Cell Signaling Technology, Danvers, MA), 
and anti-vinculin (Sigma-Aldrich, St. Louis, MO). Either anti-mouse or anti-rabbit 
secondary antibodies conjugated with horseradish peroxidase (Bio-Rad, Hercules, CA) 
were used. Bands were visualized by the enhanced chemiluminescence Western blotting 
detection system, and images were captured using the FujiFILM LAS-3000 system. 
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RNA interference 
RNAi duplexes for silencing PKCα were purchased from Dharmacon (Lafayette, 
CO).  The target sequences were: PKCα RNAi #1; CCAUCCGCUCCACACUAAA; 
PKCα RNAi # 2; GAACAAGGAAUGACUU [134].  Control silencer RNAi was 
purchased from Ambion (Austin, TX). Cells were transfected with RNAi duplexes (25 
nM) using Lipofectamine RNAi/MAX and used for the indicated experiments. 
 
Adenoviral infections 
Cells were infected with adenoviruses (Advs) for PKCα, PKCδ, or LacZ (control) 
using different multiplicities of infection (MOIs) as previously described [184] . The 
infection was carried out in RPMI 1640 medium supplemented with 2 % FBS. Complete 
medium was added 4 h later. Experiments were carried out 72-96 h later, as indicated.   
 
Cell viability assay 
Cell viability was determined using the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay kit, a colorimetric assay that contains MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
and phenazine ethosulfate (PES) with enhanced chemical stability. Cells seeded into 96-
well plates (1 × 104 cells/well) were treated with different concentrations of erlotinib for 
different times, as indicated. One h after addition of the One Solution Reagent, 
absorbance was recorded at 490 nm using a 96-well plate reader. 
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Flow Cytometry 
Subconfluent H1650 cells were detached using 0.02 % EDTA in PBS and 
washed, pelleted and resuspended in FACS buffer (PBS pH 7.2, 0.2 % bovine serum 
albumin).  5 ×106 cells were co-stained with phycoerythrin-conjugated anti-human CD24 
and allophycocyanin-conjugated anti-human CD44 (BD Biosciences, San Jose, CA) 
antibodies. Labeling was performed for 1 h at room temperature in the dark. Labeled cells 
were washed three times with the FACS buffer and sorted using a BD FACS Aria II cell 
sorter. Gates were set either at CD44/CD24 high or low expressions, and subpopulation 
of cells were collected in FACS buffer for RNA extraction. 
 
Statistical Analysis 
All statistical analyses were done using GraphPad Prism v5.03 (GraphPad 
Software, Inc., San Diego, CA). A p value < 0.05 was considered statistically significant. 
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CHAPTER 3: PKCα  signaling is required for NF-κΒ  
activation in NSCLC cells 
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3.1 Introduction 
 
Inflammation is a part of innate immunity in response to physiological and 
environmental stimuli [109]. However, persistent inflammation causes prolonged 
activation of immune cells, which results in tissue damage and risks that lead to 
neoplasia. Induction of proinflammatory cytokines, such as TNFα or IL-1β activates the 
transcription factor NF-κΒ through the canonical pathway. The activation process 
involves various signaling molecules and converges on the IκB kinase (IKK) complex, 
which consists of two closely related kinases, IKKα and IKKβ, and the regulatory unit 
NEMO. Phosphorylation and activation of this complex, particularly IKKβ, recruits and 
phosphorylates the NF-κΒ inhibitor protein, IκΒα, at serine residues followed by 
ubiquitination and subsequent degradation of the inhibitor protein. Loss of IκΒα releases 
NF-κΒ, which then translocate to the nucleus and drives transcription of multitude of 
genes. NF-κΒ is an important player in tumor progression as it is activated in chronic 
inflammation. In addition to the tumor-promoting role of NF-κΒ that involves stimulation 
of cell cycle progression, inhibition of apoptosis, increased invasive growth, and elevated 
resistance to radiation and chemotherapy, this transcription factor also participates in 
tumor initiation. For example, activated NF-κΒ in macrophages and neutrophils 
stimulates the production of reactive oxygen species (ROS) by inducing the transcription 
of inducible nitric oxide synthase (iNOS). ROS induce DNA damage and initiates lesions 
in the surrounding cells, thus contributing to tumorigenesis [74]. 
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IL-1β is a pro-inflammatory cytokine that triggers a cascade of inflammatory 
reactions through NF-κB dependent expression of genes, which also have implications in 
cancer progression. IL-1β is produced as an inactive precursor, pro-IL-1β, in response to 
injuries or infections. Following induction of pro-IL-1β expression, the precursor is 
loaded onto a multi-protein scaffold complex called the inflammasome, where it is 
cleaved by the pro-inflammatory protease caspase-1 and released out of the cells. The 
release of IL-1β into the tumor microenvironment leads to activation of inflammatory 
signals in the tumor cell and its stroma [167].  Notably, high levels of IL-1β are found in 
serum from patients with chronic lung infections and lung cancer [16, 223]. Moreover, 
exposure of lung epithelial cells to IL-1β increases expression of cyclooxygenases, 
metalloproteases and growth factors known to induce proliferation, angiogenesis and 
invasive phenotype of lung cancer cells [31, 164]. 
PKCs isozymes are pleiotropic regulators of cellular processes in lung cancer. 
Nevertheless, their functions are highly dependent on the cell type, occurrence of 
oncogenic mutations and stimuli. In the present study, we established PKCα signaling as 
an important component of NF-κΒ activation in NSCLC cells. Depletion of PKCα 
significantly attenuated IL-1β induced NF-κΒ pathway activation, including IκΒ 
phosphorylation, as well as nuclear translocation and DNA binding. Overall, these 
findings underscore the importance of PKCα signaling in the pathogenesis of lung 
cancer. 
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3.2 Results 
 
PKCs regulate NF-κΒ  activation in NSCLC cells 
Tumor infiltration of immune cells due to chronic inflammation marks the 
progression of many advanced cancer types. NF-κΒ is a well-known mediator of 
responses by proinflammatory cytokines such as TNFα and IL-1β in NSCLC. As PKC 
signaling has been linked to NF-κΒ activation in several cancer types [54, 124], we set 
out to determine if PKC signaling contributes to NF-κΒ activation in response to 
inflammatory cytokines in NSCLC. We first measured NF-κΒ activation in H460 cells in 
response to cytokines (TNFα, IL-1β) known to induce NF-κΒ transcriptional activity 
using a luciferase reporter assay. Stimulation of H460 cells with IL-1β or  TNFα led to 
an elevation in NF-κΒ luciferase activity with the highest luciferase activity being 
measured 6 h after IL-1β treatment. Next, to establish the role of PKCs in IL-1β or 
TNFα-induced NF-κΒ activation, we employed the pan PKC inhibitor GF1090203X to 
determine the effect of NF-κΒ transcriptional activity. Pre-treatment GF1090203X 
markedly attenuated cytokine-induced transcriptional activation of NF-κΒ. Notably, 
GF1090203X was most effective in inhibiting the activation of NF-κΒ in response to IL-
1β than TNFα or PMA (Fig. 3.1).  
PKCα  is required for IL-1B mediated NF-κΒ  activation 
PKCα and PKCε are found to be overexpressed in H460 cells compared to the 
normal lung epithelial cells (data not shown). As phosphorylation of IκΒα is a critical    
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Figure 3.1 PKCs are implicated in NF-κβ  activation  
 
H460 cells were co-transfected with NF-κΒ firefly luciferase reporter and pTK-Renilla 
plasmid. 24 h later, cells were pre-treated with GF1090203X (5 µM, 1 h) followed by 
treatment with TNFα  (10 ng/mL, 6 h), IL-1β (10 ng/mL, 6 h) or vehicle.  
 
step in the activation of the NF-κΒ pathway, we next assessed the effect of PKCα or 
PKCε inhibition on phospho-IκΒα levels. IL-1β-induced IκΒα phosphorylation was 
significantly attenuated by pre-treatment with either GF1090203X or a classical PKC 
inhibitor, Gö6976, thus implicating the involvement of PKCα in IL-1β induced IκΒα 
phosphorylation (Fig. 3.2A). To unambiguously demonstrate the involvement of PKCα 
in regulating IκΒα phosphorylation, we used two different RNAi duplexes to silence 
PKCα expression from H460 cells. PKCα depletion significantly reduced IL-1β-induced 
IκΒ phosphorylation and prevented IκΒ degradation (Fig. 3.2B).  
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Figure 3.2 PKCα  mediates phosphorylation of IκΒα  
 
(A) H460 cells were pre-treated with GF1090203X (5 µM, 1 h) followed by treatment 
with IL-1β (10 ng/mL, 5 min) and phosphorylated IκΒα levels were determined by 
Western blot. (B) Cells were transfected with either PKCα RNAi duplexes (α1 or α2) or 
non-target control (NTC). After 48 h, cells were treated with IL-1β (10 ng/mL) for 5 min 
and total and phosphorylated IκΒα levels were determined by Western blot. 
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To specifically ascertain the role of PKCε in IL-1β-induced IκΒα 
phosphorylation, H460 cells were pre-treated with εV1-2, a selective PKCε inhibitor 
fused with the carrier peptide Tat, which blocks PKCε translocation to membrane 
compartments and therefore prevents its activation. Contrary to the effect of Gö6976, 
εV1-2 had no effect on phospho-IκΒα levels compared to the Tat peptide control (Fig. 
3.3A). We also used RNAi for PKCε and PKCδ to rule out the involvement of the nPKCs 
in the NF-κΒ activation in H460 cells (Fig. 3.3B). Similar results were observed in 
H1975 cells (Fig. 3.3C). To further assess the role of PKCα in NF-κΒ activation in 
response to IL-1β, we took advantage of the NF-κΒ luciferase reporter. As shown in Fig. 
3.4, luciferase activity induced by IL-1β was drastically reduced in PKCα-depleted H460 
cells.  
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Figure 3.3 nPKCs do not mediate IL-1β-induced IκΒα  Phosphorylation  
 
(A) H460 cells were pre-treated either with the PKCε specific inhibitor, εv1-2 (5 µM, 1 
h) or Tat carrier peptide and phosphorylation of IκΒ was determined by Western blot. (B) 
Cells were transfected either with PKCα (α1 or α2), PKCε  (ε6 or ε8), PKCδ (δ1 or δ2) 
RNAi duplexes, or non-target control (NTC). After 48 h, cells were treated with IL-1β 
(10 ng/mL) for 5 min and total and phosphorylated IκΒα levels were determined by 
Western blot. (C) The experiments in Fig 3.3B were repeated in H1975 cells. 
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Figure 3.4 PKCα controls NF-κΒ  promoter activity 
H460 cells were transfected with either PKCα RNAi duplexes (α1 or α2) or non-target 
control (NTC). 24 h after PKCα  NTC or RNAi transfection, H460 cells were co-
transfected with NF-κΒ firefly luciferase reporter and pTK-Renilla plasmid. The 
following day, cells were stimulated with IL-1β (10 ng/mL) and luciferase activity was 
determined after 6 h using the dual luciferase reporter assay. 
 
PKCα  is critical for NF-κΒ  nuclear translocation and DNA binding 
Transcriptional regulation by NF-κΒ also depends on its translocation from the 
cytosol to the nucleus following IκΒα degradation. As activation of the NF-κΒ pathway 
leads to the relocalization of NF-κβ to the nucleus, we speculated that alteration of PKCα 
signaling may affect this NF-κΒ intracellular mobilization. We used a cell fractionation 
approach to determine the effect of PKCα on IL-1β induced NF-κΒ nuclear translocation 
in H460 cells. As expected, IL-1β promoted the translocation of NF-κΒ from the 
cytosolic to nuclear compartments. This accumulation of NF-κΒ in the nuclear fraction 
was completely blocked upon PKCα RNAi depletion (Fig. 3.5A). We then set out to 
identify whether IL-1β-induced NF-κΒ DNA binding involves PKCα signaling.  To 
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address this issue we used electrophoretic mobility shift assay (EMSA) as an approach. 
As shown in Fig. 3.5B, stimulation with IL-1β promotes an elevation in NF-κΒ DNA 
binding activity in H460 cells nuclear extracts. Remarkably, this DNA binding activity 
was attenuated in nuclear extracts from PKCα-depleted H460 cells. Taken together these 
results confirm the requirement of PKCα in NF-κΒ activation in response to IL-1β in 
NSCLC cells.  
 
 
Figure 3.5 PKCα  is critical for NF-κΒ  nuclear translocation and DNA binding 
(A) Localization of NF-κΒ was assessed in cysosolic and nuclear fractions after 1 h of 
IL-1β (10 ng/mL) stimulation in control or PKCα depleted H460 cells using Western 
blot. ATF2 and vinculin were used as loading controls for nuclear and cytoplasmic 
fractions respectively. (B) The effect of PKCα depletion on NF-κΒ DNA binding was 
measured using EMSA. The nuclear fractions were extracted 1 h after IL-1β  (10 ng/mL) 
stimulation or vehicle treatment. “F” represents free probe. 
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PKCα  overexpression in normal lung epithelial cells enhances NF-κΒ  activation  
As PKCα was found to play a significant role in IL-1β-induced NF-κΒ activation 
in lung cancer cells, we speculated that it could also have implications upon 
overexpression in normal lung epithelial cells. For these experiments, we used human 
bronchial epithelial cells (HBEC), a model of “normal” immortalized cells. HBEC cells 
were infected with different MOIs of a PKCα Adv, and LacZ Adv was used as a control. 
We observed that overexpression of PKCα potentiated IL-1β induced phospho-IκΒ levels 
(Fig. 3.6A). To further prove our hypothesis, we transfected PKCα overexpressing 
HBEC cells with the NF-κΒ luciferase reporter as shown in Fig. 3.6B, overexpression of 
PKCα by itself enhanced NF-κΒ luciferase activity. As a complementary approach, we 
measured NF-κΒ DNA binding activity in response to IL-1β in PKCα overexpressing 
HBEC cells. As expected, PKCα overexpression significantly increased NF-κΒ DNA 
binding in response to IL-1β (Fig. 3.6C). 
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Figure 3.6 Overexpression of PKCα  potentiates IL-1β  induced NF-κβ  activation in 
normal lung epithelial cells 
 
HBEC cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at different 
MOI for 72 h and treated with IL-1β (1 ng/mL, 5 min). (A) Protein levels of PKCα and 
phosphorylation of IκΒα  were analyzed by Western blot after 5 min of IL-1β 
stimulation. (B) PKCα overexpressing HBEC cells were co-transfected with NF-κΒ 
firefly luciferase reporter and pTK-Renilla plasmid. 24 h later, cells were treated with IL-
1β (1ng/mL, 6 h) and luciferase activity was determined. (C) Nuclear lysates of PKCα 
overexpressing HBEC cells treated with IL-1β (1 ng/mL) for 5 min, were extracted and 
NF-κΒ DNA binding was analyzed by EMSA. 
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PKCα  regulates the expression of NF-κΒ  target genes in normal lung epithelial and 
cancer cells 
Activation of NF-κΒ is required for the induction of genes in response to IL-1β. 
These genes are associated with survival and motility of lung cancer cells as well as 
production of a range of pro-inflammatory signals that contribute to chronic 
inflammation. Hence, to assess the functional relevance of PKCα signaling on NF-κΒ 
transcriptional activity, we analyzed the effect of altering PKCα expression in both lung 
cancer and immortalized “normal” lung epithelial cells. Treatment of H460 cells with IL-
1β induces COX-2, IL-8 mRNA levels and MMP9 expressions. Interestingly, the 
induction in these NF-κΒ regulated genes by IL-1β was essentially abolished in PKCα-
depleted H460 cells (Fig 3.7). 
Next we overexpressed, we also overexpressed PKCα in HBEC cells using 
adenoviral approach. IL-1β stimulation resulted in a marked elevation of COX-2 and 
MMP9 mRNA levels in HBEC. PKCα potentiated the induction of COX-2 and MMP9 in 
HBEC cells. For IL-8, Il-1b caused a very high induction (~40-fold) in HBEC cell, and 
PKCa overexpression was unable to cause additional effect (Fig. 3.8).  
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Figure 3.7 PKCα  regulates expressions of NF-κΒ  target genes in NSCLC cells 
H460 cells were transfected with either PKCα RNAi or NTC. After 48 h, cells were 
treated with IL-1β (10 ng/ml) and RNA was isolated after 6 h. Gene expression of Cox-2, 
MMP9, and IL-8 was analyzed using qPCR.
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Figure 3.8 Overexpression of PKCα  potentiates IL-1β-induced expression of NF-κΒ  
target genes in NSCLC cells 
Normal lung epithelial (HBEC) cells were infected with either LacZ or PKCα Adv (100 
MOI) for 72 h and stimulated with IL-1β (10 ng/ ml) for 6 h. RNA was isolated and gene 
expression of Cox-2, MMP9, and IL-8 was analyzed using qPCR.   
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3.3 Discussion 
 
There are ample reports implicating PKC isozymes in tumorigenesis. However, 
the specific contribution of individual PKC isozymes to various cellular processes that 
hallmark the initiation and progression of cancer remains only partially understood. This 
is also true for lung cancer, where PKC isozymes have been implicated in lung cancer 
malignancy, but their individual roles have not been yet fully characterized. In this study, 
we investigated whether PKCs are implicated in controling the activation of the NF-κΒ 
pathway in NSCLC. Our results show PKCα regulates the various steps required for NF-
κΒ activation in NSCLC cells. Notably, PKCα depletion impairs NF-κΒ activation as 
well as induction of NF-κΒ target genes in response to IL-1β, arguing for an important 
role for PKCα in lung cancer progression. 
 The transcription factor NF-κΒ plays an important role in host immune 
mechanisms. During inflammation, binding of pro-inflammatory cytokines such as TNFα 
or IL-1β to their respective receptors results in activation of NF-κΒ. Activation of NF-κΒ 
is normally associated with acute inflammatory signals that involve chemokine-and 
adhesion molecule-mediated recruitment and activation of immune cells, mainly 
neutrophils to the site of inflammation. These acute inflammatory signals eliminate 
transformed cells and protect the body against cancer risks. However, during chronic 
inflammation, the role of NF-κΒ becomes more complex and multifold [13, 71]. On one 
hand, continuous induction of pro-inflammatory factors by NF-κΒ during chronic 
inflammation results in DNA damage, leading to oncogenic mutations. On the other 
hand, to withstand physiological stress caused by chronic inflammation, NF-κΒ promotes 
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cell survival and proliferation by regulating the expression of proteins implicated in cell 
cycle cycle control (e.g. cyclin D, c-myc) and apoptosis (e.g. IAP, Bcl-2), adding to its 
tumorigenic effects [109, 122].  
The advanced lung cancer inflammation index (ALI) is used as a prognostic and 
treatment outcome marker for lung cancer patients, thus underscoring the significance of 
chronic inflammation in disease pathogenesis [84]. Chronic airway inflammation 
contributes to alterations in the bronchial epithelium and the lung microenvironment, 
paving a way for lung carcinogenesis. Additionally, lung cancer risk factors such as 
chronic obstructive pulmonary disease and chronic pulmonary infections are 
characterized by an inflammatory state. Lung tumors also exhibit high levels of 
inflammatory mediators such as ROS, cytokines, chemokines, and eicosanoids, which are 
associated with cancer initiation [67].  
Cigarette smoke is the main cause of oxidative stress and etiological factor that 
induces lung cancer by generating ROS leading to tissue destruction. Inflammation due to 
smoking results in NF-κΒ dependent up-regulation of pro-inflammatory cytokines 
including TNFα, IL-1β, IL-8 and IL-6. Moreover, lung tumors and serum collected from 
lung cancer patients are reported to have elevated levels of inflammatory markers (C-
reactive protein) and chemokines (such as CXCL13 and CCL22) that regulate migration 
of lymphocytes to the site of inflammation. Similarly, high levels of the p65 unit of NF-
κΒ were found in NSCLC compared to the normal lung epithelium [222]. Furthermore, 
IKKα/β independent activation of NF-κΒ in response to growth factor receptors was 
found to be important for the survival of NSCLC cells and NF-κΒ inhibition attenuated 
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the survival of lung cancer cells [29]. In addition to tobacco smoke, other environmental 
carcinogens have been causally linked NF-κΒ activation in lung tumors. Urethane-
induced lung tumor development was attenuated in mice with genetic depletion of the 
CCR5 chemokine. The CCR5-/- mice were shown to have reduced NF-κΒ activity 
compared to the wild type mice [98]. Other studies using mouse models have also shown 
the effect of constitutive NF-κΒ activation in the development of pulmonary 
adenocarcinoma. Elevated NF-κΒ activity was also reported in KRAS+/-;p53-/- mice and 
KRAS-driven lung tumors were attenuated upon NF-κΒ inhibition [10, 118].  
Previous studies argued for a connection between PKC isozymes and the NF-κΒ 
pathway activation. Initial links in cancer were reported for the aPKCs. Indeed, PKCζ 
phosphorylates NF-κΒ upstream kinase IKKβ at ser-177 and ser-181 in response to 
TNFα. Additionally PKCζ-/- mice have attenuated RelA binding activity [40]. The other 
aPKC isozyme, PKCι also mediates phosphorylation of IKKβ in response to TNFα and 
induces NF-κΒ dependent transcription of the IL-6 gene in prostate cancer [106]. 
Recently, our laboratory identified a key role for PKCε in TNFα-dependent activation of 
NF-κΒ in prostate cancer. PKCε was shown to be a part of the TNFRI signaling complex 
that leads to NF-κΒ activation [54]. Yet other novel PKC isozyme, PKCδ was reported to 
facilitate RelA binding to the promoters of target genes [110]. Activation of the NF-κΒ 
pathway is also attributed, in part, to alterations in cPKCs. PKCβ-dependent activation of 
NF-κΒ, through modulation of the IKK complex, was found to be crucial for the survival 
Chronic lymphocytic leukemia [111, 123]. Using in vitro binding assays, it has been 
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shown that PKCα forms a complex with the NF-κΒ upstream kinase, IKK [192]. 
Additionally PKCα has been shown to interact with IKKβ in response to PMA in 293T 
cells. The mechanism for PKCα-dependent NF-κΒ  activation was also extended to 
phosphorylation of RelA in glioma cells [126]. It has been reported that PKCα mediates 
NF-κΒ activation in A549 NSCLC cells in response to TNFα [97].  
IL-1β has been shown to induce NF-κB signaling in many cell types. Not 
surprisingly, we found that IL-1β treatment activates the NF-κB pathway in H460 cells as 
manifested by IκBα phosphorylation and NF-κΒ promoter activity. High levels of IL-1β 
are found both in NSCLC cells and within the tumor microenvironment [167]. 
Additionally, polymorphisms in the IL-1β gene have been associated with increased risk 
of NSCLC [223], an indication of the significance of IL-1β-mediated signals in the 
pathogenesis of this disease. Here, we showed that depletion of PKCα prevents IL-1β-
induced NF-κΒ activation as determined by decreased IκΒα phosphorylation, NF-κΒ 
relocalization to the nucleus, NF-κΒ promoter activity, and DNA binding. Studies using 
cellular and animal models have shown diverse implications of PKCα signaling in lung 
cancer. For example, PKCα up-regulates the cell cycle inhibitor p21 and confers a 
senescent phenotype in NSCLC cells [133]. In KRAS mutant mice, PKCα genetic 
silencing inhibited oncogene driven lung tumorigenesis [73]. However, there are also 
reports of PKCα as a positive regulator of growth and cell motility in NSCLC [31]. 
PKCα was shown to mediate ERK activation in the RAS signaling cascade [163]. 
Additionally, aprinocarsen, an antisense oligonucleotide against PKCα, has been used in 
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clinical trials for NSCLC patients. This antisense potentiates chemotherapeutic activity of 
carboplatin and paclitaxel in phase II trials although it did not enhance the overall 
survival of patients in phase III studies [137, 151]. In line with our results, Song et al. 
recently showed that inhibition of PKCα led to apoptosis in H460 NSCLC cells [165]. 
In contrast to the effects of PKCα, neither inhibition of PKCε nor PKCδ 
significantly attenuated NF-κΒ activation in NSCLC cells. These findings suggest that 
IL-1β-dependent NF-κΒ activation in H460 cells is highly dependent on PKCα. The role 
of PKCα in response to IL-1β is not only limited to the cancer cells, but we also observed 
elevation of IκΒα phosphorylation and NF-κΒ DNA binding in normal immortalized 
lung epithelial cells upon PKCα overexpression. The various biological effects of NF-κΒ 
depend on its regulation of target gene expressions. Our findings show that PKCα-
mediated activation of NF-κΒ by IL-1β results in up-regulation of NF-κΒ responsive 
genes involved in cell survival, motility, angiogenesis and inflammation. 
 
Summary 
Our results have demonstrated that inhibition of PKCα controls the activation of 
the NF-κΒ pathway. PKCα RNAi attenuates IL-1β induced expression of NF-κΒ 
responsive genes by decreasing NF-κB transcriptional activity. Overall, these findings 
support the notion that distinctive PKCs play a central role in controlling the activation of 
the NF-κΒ pathway.  
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3.4 Materials and Methods 
 
Cell culture and reagents 
The Human lung adenocarcinoma cell lines H460 and H1975 were obtained from 
ATTC (Manassas, VA) and cultured in RPMI 1640 medium supplemented with 10 % 
FBS (Hyclone, Logan, UT), 100 U/mL penicillin, and 100 µg/mL streptomycin (Life 
Technologies, Grand Island, NY). Immortalized human bronchial epithelial cells (HBEC) 
were a kind gift from Dr. Trevor Penning (University of Pennsylvania, PA) and were 
cultured in KSFM medium supplemented with 0.05 mg/mL bovine pituitary extract and 5 
ng/mL EGF purchased from Life Technologies. Cells were maintained at 37°C in a 
humidified 5 % CO2 atmosphere. IL-1β was purchased from R&D Systems 
(Minneapolis, MN) and used at 1 and 10 ng/mL concentrations. The NF-κΒ firefly 
luciferase reporter was a kind gift from Dr. Dave Manning (University of Pennsylvania, 
PA). PMA and the cPKC inhibitor Gö6976 were obtained from LC laboratories (Woburn, 
MA). The pan-PKC inhibitor GF109203X was procured from Enzo Life Sciences 
(Plymouth meeting, PA). The PKCε peptide inhibitor εV1-2 and the carrier peptide Tat 
were kind gifts from Dr. Daria Mochyl-Rosen (Stanford University, CA). 
 
Western blots 
Western blot analysis was carried out as described on page 68. The following 
primary antibodies were used in 1:1000 dilutions: anti-PKCα (EMD Millipore Corp., 
Billerica, MA), anti-PKCε, anti-IκΒα, NF-κΒ p65 (Santa Cruz Biotechnology, Santa 
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Cruz, CA), anti-PKCδ, anti-phospho-IκΒα (Cell Signaling Technology, Danvers, MA) 
and 1:50,000 dilutions of anti-vinculin (Sigma-Aldrich, St. Louis MO).  
 
Adenoviral infections  
Adenoviral infection was carried out as described on page 69.  
 
RNA interference 
RNA interference was carried out as described on page 69.  
 
Luciferase Reporter Assay 
Cells in 12-well plates (1 × 105 cells/well) were transfected with 0.45 µg of a NF-
κB firefly luciferase reporter vector and 0.05 µg of the Renilla luciferase expression 
vector pRL-TK (Promega, Madison, WI) using Lipofectamine 2000 (Invitrogen). The 
DNA/ Lipofectamine 2000 mixture was incubated for 20 minutes and added onto 
adherent cells in antibiotic free media. Renilla luciferase vector was used as an internal 
control to normalize the transfection efficiency. After 24 h, cells were treated with IL-1β 
or vehicle and lysed 6 h later with passive lysis buffer (Promega). Luciferase activity was 
measured using the dual-luciferase reporter assay system. The results were expressed as a 
ratio of Firefly to Renilla luciferase activities in relative luciferase units (RLU). 
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Preparation of nuclear extracts  
Cytoplasmic and nuclear extracts were obtained as described previously [155]. 
Briefly, cells were collected in ice-cold PBS and centrifuged to collect the cell pellets. 
Next, cells were resuspended in 250 µl of hypotonic buffer (20 mM HEPES pH 7.9, 10 
mM KCl, 1 mM EDTA, 10 % glycerol, 0.2 % Igepal and protease inhibitors) for 10 min. 
Lysed cells were centrifuged (2000 × g) for 1 min and the supernatant containing the 
cytoplasmic extract was removed. Incubation in hypotonic buffer and centrifugations 
were repeated three times to clean the nuclear pellet. The pellet was then resuspended in 
100 ml hypertonic buffer (240 mM NaCl, 20 mM HEPES pH 7.9, 10 mM KCl, 1 mM 
EDTA, 20 % glycerol, 0.2 % Igepal, and protease inhibitors) and incubated for 30 min at 
4°C. After 15 min centrifugation (12000 × g), the supernatant (nuclear extract) was 
collected. Both cytoplasmic and nuclear fractions were stored at -80°C until use. 
 
Electrophoretic mobility shift assay (EMSA) 
EMSA was carried out as described previously [54]. Briefly, an NF-κB 
oligonucleotide probe (5′-agcttGAGGGGATTCCCTTA-3′) was labeled with [α-32P] 
dATP using Klenow enzyme. Following purification on a Sephadex G-25 column, the 
binding reaction was carried out at 25 °C for 10 min in two sets. The first set contained 5 
µg of nuclear proteins, 1 µg of poly (dI-dC), and 106 cpm of labeled probe in a final 
volume of 20 µl of binding buffer (10X buffer: 100 mM Tris-HCl pH 7.5, 500 mM NaCl, 
50 mM MgCl2, 100 mM EDTA, 10 mM DTT, 1 % Triton X-100, and 50 % glycerol), 
while the second set had no nuclear extracts. To show a binding specificity, 50-fold molar 
93 
 
excess of cold NF-κΒ probe and cold AP-1 probe were used. In the reaction, DNA-
protein complexes and unbound probe were separated electrophoretically on 6 % non-
denaturing polyacrylamide gels in 0.5X TAE buffer at 200 V. The gel was dried, 
followed by autoradiography at -80°C. 
 
RNA isolation and DNA synthesis 
RNA isolation and DNA synthesis was carried out as described on page 68. 
 
Real-time PCR 
Quantitative real time PCR was carried out as described on page 68. Primers and 
fluorogenic probes for PKCα, COX-2, IL-8, MMP9 and 18S were purchased from 
Applied Biosystems.  
 
Statistical Analysis 
All statistical analyses were done using GraphPad Prism v5.03 (GraphPad 
Software, Inc., San Diego, CA). A p value < 0.05 was considered statistically significant. 
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Chapter 4: PKCε  is required for KRAS-driven lung 
tumorigenesis 
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4.1 Introduction 
 
 KRAS mutations have been identified in approximately 30 % of human lung 
adenocarcinomas [41, 87]. KRAS is a member of the RAS small GTPase superfamily and 
functions to propagate mitogenic and survival signaling through activation of the MAPK 
cascade and PI3K pathway [87] . Thus, RAS mutations result in uncontrolled stimulation 
of these signaling pathways and contribute to tumorigenesis. KRAS mutations are 
detected in precancerous lesions of lung adenocarcinoma suggesting their role in the 
initiation of human lung cancer. Similarly, KRAS mutations were the first molecular 
alterations identified in mouse lung tumors and mutation of KRAS is a major early event 
in the carcinogenic process of both spontaneous and chemically-induced mouse lung 
tumors [83, 202], suggesting that mouse lung tumorigenesis may at least partly model 
human lung cancer [129]. Several distinct mouse models that express mutant KRAS at 
physiologically normal levels have been generated and show that mutation in this 
oncogene is sufficient to drive proliferation and induce the formation of lung 
adenocarcinomas [42, 117, 129] . One of these models is the LSL-KRASG12D mice, in 
which expression of oncogenic KRASG12D is expressed in the mouse lung upon delivery 
of Cre-recombinase. This leads to the development of lung lesions, ranging from atypical 
adenomatous hyperplasia to adenocarcinomas. This animal model thus recapitulates the 
stages of tumor progression found in NSCLC patients [42]. 
PKCε is an oncogenic kinase that is dysregulated in many cancers including 
NSCLC. Overexpression of PKCε is reported in more than 90 % of primary NSCLC 
cancers relative to the normal lung epithelium [7]. Several studies from our laboratory 
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underscored the importance of PKCε in lung cancer progression. We previously reported 
that PKCε regulates NSCLC cell proliferation, growth and tumorigenicity in nude mice. 
Indeed, PKCε RNAi depletion from NSCLC cells reduces anchorage-dependent and 
anchorage-independent growth in H358 and A549 cells. Moreover, NSCLC growth in 
xenografts in nude mice is substantially impaired by PKCε RNAi depletion or treatment 
with the specific PKCε inhibitor εV1-2 [25]. Additionally, our lab has shown that PKCε 
is required for the activation of the small GTPase Rac1 and in this way it controls 
NSCLC cell motility and invasiveness through regulating the secretion of 
metalloproteinases [26]. PKCε also regulates the expression of anti-apoptotic genes such 
as Bcl-2 and IAP-2 [12, 63] and controls G1 to S transition in the cell cycle [19, 49]. 
Additionally, it was previously reported that PKCε depletion sensitizes lung cancer cells 
to TRAIL-induced cell death [47].  
A growing body of evidence indicates that PKCε is implicated in the initiation 
and maintenance of cancer phenotype. Early studies revealed that overexpression of 
PKCε in fibroblasts and colonic epithelial cells leads to malignant transformation, which 
includes morphological changes, anchorage-independent growth, and increased 
tumorigenesis in nude mice [23, 119, 177]. Overexpression of PKCε was found to 
transform androgen-dependent prostate cancer cells (LNCaP) to androgen-independent 
cancer cells [206]. Additionally, our laboratory showed that overexpression of PKCε in 
the mouse prostate is sufficient to induce preneoplastic lesions [18], as well as it 
cooperates with PTEN loss to induce prostate adenocarcinoma (unpublished results). In 
skin tumor animal models, PKCε overexpression also resulted in hyperplasia, 
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hyperkeratosis and the development of skin squamous cell carcinoma in mice treated with 
DMBA and a phorbol ester [6]. Thus, it is conceivable that PKCε is implicated in tumor 
initiation in lung cancer.   
Several studies implicated PKCε in RAS signaling in cancer. PKCε can be 
activated by KRAS and is required for RAF-induced cell transformation. Inhibition of 
PKCε attenuated NIH 3T3 and Cos-1 cell proliferation similar to dominant negative RAS 
and RAF. Moreover, it has been shown that PKCε binds to the RAF kinase domain and 
activates its kinase activity by direct phosphorylation [5, 23]. There have been reports 
suggesting a link between PKCε and chemically-induced lung carcinogenesis. Indeed, 
PKCε depletion was found to suppress cell growth in response to tobacco smoke. At the 
mechanistic level, activation of PKCε by ROS generated from tobacco smoke recruits 
and phosphorylates the metalloprotease TACE/ADAM-17. Activation of TACE results in 
the cleavage of amphiregulin, leading to transactivation of EGFR [100]. PKCε has been 
further implicated in the induction of nitric oxide synthase (iNOS), predisposing smokers 
to lung cancer [131]. However, a link between PKCε and KRAS tumorigenesis in vivo 
still remains to be established.  
Here, we examined the requirement for PKCε in lung tumorigenesis in vivo by 
using a mouse model. We found that genetic inhibition of PKCε significantly attenuates 
KRAS-driven initiation of lung tumors. Additionally, we initiated the generation of an 
inducible lung specific PKCε mouse model to study if the overexpression of PKCε is 
sufficient to promote the formation of preneoplastic or neoplastic lesions. 
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4.2 Results 
 
Generation of KRASG12D; PKCε -/-mice 
Oncogenic KRAS-driven mouse models of lung adenocarcinoma have enabled 
the study of tumor initiation and progression in vivo. In order to determine whether PKCε 
cooperates with KRAS to promote lung tumor formation, we created a mouse model in 
which mutated active KRAS was conditionally expressed in PKCε heterozygous or 
knockout backgrounds. Previous studies have reported that PKCε knockout mice display 
decreased tolerance to alcohol, delayed pain signals and reduced acute cardio protection, 
but other than that there are no obvious general abnormalities. Experimental mice were 
developed by crossing mice harboring a conditional activated KRAS allele (LSL-
KRASG12D) with PKCε knockout mice. To achieve the PKCε knockout background, we 
first interbred the PKCε-/+ progeny. In the KRAS model, mutant is expressed as 
heterozygous whereas homozygotes die in utero [42]. Spontaneous lung tumor initiation 
is achieved by intranasal delivery of Cre-recombinase to the lungs using an adenovirus 
(Ad-Cre). This leads to removal of the transcriptional stop element and expression of the 
oncogenic KRAS. To generate the bitransgenic KRASG12D;PKCε-/- mice, we used two 
approaches. The strategies involved crossing KRASG12D;PKCε+/- mice with PKCε-/- mice, 
and KRASG12D;PKCε+/- mice with PKCε+/- mice, which had 25 % and 12.5 % chance of 
achieving the experimental mice, respectively (Fig. 4.1). The bitransgenic mice appeared 
normal at birth and did not display any signs of abnormalities during adulthood. The 
deletion of PKCε gene (PRKCE) and the expression of mutant KRAS were verified using 
qPCR (Fig. 4.2A and 4.2B).   
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Figure 4.1 Breeding strategies to generate the KRASG12D;PKCε -/- mice 
PKCε knockout mice were crossbred with KRAS mutant mice. The F1 progeny were 
crossed either with PKCε heterozygous or PKCε knockout mice to generate the KRAS 
mutant in PKCε null background.   
Parents allele Combination 
Father P-P- K+K+ P-K+  
Mother P+P+K+K- P+K+, P+K- 
F1 P+K+ P+K- 
P-K+ P-/+K+/+ P-/+K+/- (50 %) 
First generation 
Strategy 1  
PKC!-/- ! KRASG12D;PKC!-/+ (F1) 
 
F2 P-K+ 
P+K+ P+/-K+/+ 
P+K- P+/-K-/+ 
P-K+ P-/-K+/+ 
P-K- P-/-K-/+ 
Strategy 2 
 PKC!-/+ ! KRASG12D;PKC!-/+ (F1) 
 
F2 P+K+ P-K+ 
P+K+ P+/+K+/+ P+/-K+/+ 
P+K- P+/+K-/+ P+/-K-/+ 
P-K+ P-/+K+/+ P-/-K+/+ 
P-K- P-/+K-/+ P-/-K-/+ 
Second generation 
PKC!-/- ! KRASG12D 
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Figure 4.2 KRASG12D and PKCε  mutant mice genotyping 
(A) Genomic DNA was extracted and status of wild-type, heterozygous or homozygous 
PKCε allele was assessed by PCR. (B) Status of wild-type or mutant KRAS allele was 
assessed by PCR.  
 
Genetic ablation of PKCε  attenuates tumor formation by KRAS 
Given the observation that PKCε and KRAS are dysregulated in a large 
proportion of lung tumors, we asked whether loss of PKCε expression affects the 
formation of KRAS-driven tumors. It has been reported that 12 to 16 weeks following 
Ad-Cre administration, KRAS mice develop adenocarcinomas and die within 24 to 26 
weeks after activation of the oncogene [42, 83, 92]. To evaluate the effects of PKCε 
deletion in vivo, we randomized mice into three groups; KRASG12D;PKCε+/+, 
A 
PKC! allele 
1 2 3 4 5 
PKC! WT 
PKC! homozygous 606 bp  
500 bp  
B 
G12D 
WT 
KRAS allele 
507 bp 
600 bp 
1 2 3 4 5 
101 
 
KRASG12D;PKCε+/- and KRASG12D;PKCε-/-. Mice were exposed to Ad-Cre at 6 to 8 
weeks-old. Interestingly, KRAS-driven tumor formation in either PKCε heterozygous or 
PKCε knockout mice was significantly reduced compared to KRAS mutant mice with 
PKCε wild-type background. Therefore, loss of one PKCε allele was sufficient to 
significantly affect lung tumor initiation (Fig. 4.3A). Neither the KRASG12D;PKCε+/- nor 
the KRASG12D;PKCε-/- mice had incidence of extensive tumors. Indeed, 83.3 % of the 
KRASG12D;PKCε+/+ mice developed extensive tumors, whereas only 53.8 % of the 
KRASG12D;PKCε+/- or KRASG12D;PKCε-/- mice had small patchy areas of tumors. 
Histological analysis also revealed that while KRASG12D;PKCε+/+ mice have multifocal 
lung lesions, the lesions were markedly reduced in PKCε heterozygous mice and nearly 
absent in a PKCε-null background (Fig. 4.3B). 
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Figure 4.3 Genetic inhibition of PKCε  impairs lung tumorigenesis by mutant KRAS 
 
(A) Histological scoring system for lung tumors formed in the bitransgenic 
KRAS
G12D
;PKCε
-/+
 and KRAS
G12D
;PKCε
-/- or KRAS
G12D
 mice.  0 = minimal tumor seen; 1 
= small patchy areas of tumors; 2 = extensive lung tumors.  (B) Representative 
histological sections of KRAS
G12D
 , KRAS
G12D
;PKCε
-/+
 and KRAS
G12D
;PKCε
-/-
 lungs 12 
weeks postinfection with Ad-Cre (5 × 105 PFU). 
  
B 
KRASG12D;PKC!+/-  KRASG12D;PKC!-/-  KRASG12D;PKC!+/+  
12 wk 12 wk 12 wk 
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Generation of pTRE-PKCε  Mice 
We have previously shown that PKCε is required for NSCLC cells growth and 
tumorigenicity in nude mice [25, 26]. Studies have indicated that there is a causal 
relationship between up-regulation of PKCε and cancer initiation in prostate and skin 
cancer [6, 18]. We sought to investigate the phenotypic consequence of overexpressing 
PKCε in the normal lung in vivo. As an approach we generated a transgenic mouse model 
in which PKCε was specifically expressed in the lungs. In an inducible manner, PKCε 
cDNA was inserted into a modified pTRE-tight promoter vector to generate a cassette 
which contained the tetracycline-responsive element (TRE), minimal CMV promoter, N-
terminal HA-tag and the PKCε gene. This construct allows turning transgene expression 
“on” and “off" by doxycycline treatment. To validate the expression of PKCε, COS-1 
cells were transiently co-transfected with pTRE-PKCε and pTetON plasmid. 24 h later, 
cells were treated with increasing concentrations of doxycycline. We found a 
concentration dependent elevation in PKCε expression in COS-1 cells (Fig. 4.4A). The 
results were also further confirmed in MCF-7 cells that stably express the reverse 
transcription transactivator (rtTA). In the presence of doxycycline, rtTA enabled the 
expression of PKCε upon binding to the Tet-responsive element (Fig. 4.4B). Following in 
vitro validations, linearized plasmid was microinjected into the pronucleus of fertilized 
zygotes of S129/B6 mice and implanted into a pseudo-pregnant foster mother. Chimeric 
mice were analyzed by Southern blot to select founders for transgenic lines. To detect the 
PKCε transgene, an endogenous PKCε probe was used. As shown in Fig. 4.5, an 
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additional band was detected in DNA samples from the PKCε transgenic mice. This band 
was absent in samples from wild-type C57BL/6 or mice the lack the transgene insertion. 
 
 
 
Figure 4.4 Validation of pTRE-PKCε  vector construct before pronuclear 
microinjection 
(A) Cos-1 cells were co-transfected with pTet-On and pTRE-PKCε. The expression of 
PKCε under the control of a tetracycline (Tet)-inducible promoter in response to different 
concentrations of doxycycline was verified by Western blot.  (B) MCF-7 Tet-On cells 
were transfected with pTRE-PKCε and the expression of PKCε upon doxycycline 
treatment was detected by Western blot. 
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Figure 4.5 Identification of transgenic founder lines 
Genomic DNA was extracted from two wild-type and seven pTRE-PKCε transgenic mice 
and digested overnight with BglII restriction enzyme. An endogenous PKCε sequence 
was used as a probe and the number of pTRE-PKCε integrations in the genome was 
assessed by Southern blot.  
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4.3 Discussion 
 
PKCε  as a mediator of KRAS tumorigenesis 
KRAS is a common mutation in many cancers, and the identification of mediators 
of KRAS signaling is important to successfully develop therapeutic approaches. While 
the oncogenic role of KRAS gene is widely established, the molecular effectors 
responsible for its effects in lung cancer have not yet been fully elucidated. Here we 
found that PKCε is required for KRAS-driven tumorigenesis in lungs. Genetic loss of 
PKCε results in attenuated tumor formation upon activation of oncogenic KRAS in 
mouse lungs. Notably, loss of one allele was sufficient to significantly inhibit KRAS-
dependent lung tumorigenesis.    
Lung-specific KRAS mutant mouse models have been widely used for 
understanding the biology associated with KRAS-induced lung carcinogenesis. Three 
different strategies have been previously used to express mutant KRAS for inducing lung 
tumors in vivo. First, expression of a doxycycline-regulated KRASG12D transgene was 
achieved using transgenic mice expressing reverse tetracycline transactivator transgene 
under the control of surfactant factor C (SPC) promoter. In this model, tumor formation is 
induced by doxycycline and the expression of KRASG12D can be turned “on” and “off” at 
different time points [104]. The second strategy involves somatic recombination that 
results in expression of KRASG12D. Although most tumors are formed in the lungs, 
studies also reported tumors in other tissues [117]. The third model, LSL-KRASG12D, 
which is the model we used in our studies, involves the expression of mutant KRAS upon 
Cre-mediated removal of a stop codon sequence flanked by loxP. Cre-recombinase is 
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delivered to the lungs either by an infection with adenoviral vector or by crossbreeding 
with mice that express Cre under the control of an SPC promoter. All three models 
ultimately result in the formation of lung tumors [83].  
Using LSL-KRASG12D mice, several studies have identified downstream effectors 
of KRAS in lung tumorigenesis. For example, deletion of NOS2 attenuated lung tumor 
formation in mice expressing oncogenic KRAS [131]. The small GTPase Rac1 has also 
been implicated in KRAS-induced lung cancer. KRASG12D;Rac1-/- mice showed delayed 
tumor initiation, and the tumor to lung volume ratio was significantly reduced compared 
to the Rac1 wild-type control mice [92]. Our studies suggest that PKCε is another key 
effector in the initiation of KRAS-driven lung tumors. Twelve weeks after Ad-Cre 
infection, KRAS mutant mice with PKCε heterozygous or knockout background had 
reduced tumor incidence compared to KRASG12D;PKC+/+ mice. These results are 
consistent with a tumor promoting role of PKCε in primary human NSCLC tumors. 
Indeed, previous studies from our laboratory revealed that RNAi depletion of PKCε from 
NSCLC cells results in significant inhibition of anchorage-dependent and independent 
growth. Moreover, silencing PKCε in KRAS mutant NSCLC cells, such as A549, H441, 
H358 and H322 cells reduced growth, proliferation and resulted in decreased metastatic 
dissemination in xenograft models [25].  
Our results raise a number of interesting questions for subsequent work, including 
what role PKCε plays in maintenance of KRAS-induced lung tumors, as well as what 
mechanisms and downstream effectors of PKCε mediate KRAS signaling. To establish 
the important role of PKCε in tumor maintenance, we have initiated a survival 
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experiment. In this experiment, 6-8 weeks old KRASG12D;PKCε+/+ and KRASG12D;PKCε+/- 
mice were infected with Ad-Cre, and mice are being observed until they require 
euthanasia due to tumor burden. We expect differential survival rates between mice with 
PKCε wild-type and heterozygous backgrounds. Due to the tumorigenic role of PKCε in 
lung cancer, the KRASG12D;PKCε-/+ mice are expected to live longer. However, we can 
only speculate on the tumor burden differences at the time of death between the two 
groups.  In a study that analyzed the role of Rac1 using similar KRAS-driven mouse lung 
tumor models, Rac1 was shown to delay tumor initiation. Additionally, KRAS mutant 
mice in a Rac1 knockout background survived longer post-infection with Ad-Cre [92].  In 
the KRASG12D;NOS2-/- model, mice had increased tumor latency, decreased tumor 
growth, and longer survival time compared to the KRASG12D mice in NOS2+/+ 
background. At the time of death, NOS2 wild-type mice had 100 % incidence of at least 
one carcinoma, while the incidence was slightly reduced to 89.5 % in NOS2 knockout 
background [131]. Since PKCε has been implicated in the regulation of both Rac1 and 
NOS2 in lung cancer and also has tumorigenic capacity in NSCLC cells in vitro, we 
expect that KRASG12D; PKCε-/- mice, will display significant decrease in tumor size. 
Several other effectors of PKCε could mediate its tumorigenic capacity. Studies from our 
laboratory revealed that lesions that developed in mice overexpressing PKCε in the 
prostate exhibited elevated Akt activation [18]. Additionally, depletion of Akt in mice 
that harbor a latent activatible mutant KRAS (KRASLA2/+) resulted in reduced lung tumor 
formation. Akt has also been implicated in chemically-induced lung carcinogenesis [76, 
89]. The Erk/MAPK cascade and the Stat3 pathways are other potential mechanisms by 
109 
 
which PKCε could drives tumor formation in the lungs as both are well-established PKCε 
effectors in other models [5].  
 
Inducible model for PKCε  in mouse lungs  
We aimed to inducibly overexpress PKCε in the lungs to recapitulate the scenario 
observed in cancer patients. Additionally, by turning off the overexpression of PKCε, we 
can determine if the kinase is important for the maintenance of lung tumors. The pTRE-
PKCε mouse model we generated will hopefully results in the overexpression of PKCε 
specifically in the lung when crossed with SPC-rtTA transgenic mice. SPC is exclusively 
expressed in type II alveolar epithelia cells, which are sites of lung cancer occurrence. 
The bitransgenic mice, SPC-rtTA-PKCε mice will express the reverse tetracycline 
controlled transactivator (rtTA) protein under the control of the human SPC promoter. 
rtTA then binds to the promoter of the tetracycline element (pTRE) and drives the 
expression of PKCε in the presence of doxycycline [42, 83]. An additional advantage of 
the pTRE-PKCε mice is that they can be used to generate other tissue-specific transgenic 
models by crossing with appropriate mouse models that direct transgene expression in 
different cell types. 
As we are currently optimizing the PCR assay for genotyping the pTRE-PKCε 
mice, we can only speculate about the phenotypic outcome of the SPC-rtTA-PKCε mice 
at this stage. Previously our lab has generated transgenic mice that overexpress PKCε in 
the mouse prostate under the control of the probasin promoter. Overexpression of PKCε 
in these transgenic mice led to the development of preneoplastic lesions, which 
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progressed to invasive adenocarcinoma of the prostate in a PTEN-deficient background. 
Similar results are expected from the lung-specific PKCε mice where overexpression of 
PKCε may lead to precancerous lesions of the lung. To develop adenocarcinoma of the 
lungs, PKCε may require cooperation from other genetic alterations such as KRAS or 
EGFR mutations. Similarly, the requirement of carcinogens for PKCε-dependent tumor 
progression from hyperplasia to carcinoma was seen in skin-specific PKCε 
overexpressing mice. Although these mice developed hyperplasia, squamous cell 
carcinoma was induced 12 weeks after combinational treatment with DMBA and a 
phorbol ester [6]. 
Summary 
Here we have presented evidence showing the requirement of PKCε for KRAS 
induced mouse lung tumors using a bitransgenic KRASG12D;PKCε-/- mouse model 
generated in our lab. We have also generated a pTRE-PKCε mouse model that can be 
used for lung-specific overexpression of PKCε in an inducible manner. These animal 
models will enable us to elucidate the diverse roles PKCε plays in the initiation and 
maintenance of lung tumors. Additionally, the lung-specific PKCε overexpressing mice 
will enable us to delineate oncogenic alteration that cooperate with PKCε to promote 
lung tumors in vivo.  
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4.4 Material and Methods 
 
Mice Strains 
PKCε -/+ mice were developed in the laboratory of Dr. Robert Messing (UCSF) as 
described previously [91]. Briefly, a mouse genomic PKCε sequence with depletion of 
the start codon was inserted to a recombination vector. The linearized construct was 
electroporated into embryonic stem cells. Clones were selected in culture in the presence 
of hygromycin and neomycin and analyzed for predicted homologous integration. 
Recombinant clones was then microinjected into blastocysts and implanted in pseudo-
fertilized mice. The chimeric mice were crossed with C57BL/6 WT mice. LSL-KrasG12D 
heterozygous mice (B6.129-Krastm4Tyj), originally developed by Dr. Tyler JackS, was 
obtained from Jackson laboratories. Briefly, the G12D mutation was inserted in exon 1 of 
the KRAS gene followed by insertion of loxP-flanked stop element in intron 1, upstream 
of the mutation. The linearized vector was electroporated into embryonic stem cells. The 
chimeric mice was backcrossed to C57BL/6 for more than 10 generations by The Jackson 
Laboratory.   
 
KRASG12D and PKCε  mutant mice genotyping 
To genotype mice, genomic DNA was extracted from tail clippings and analyzed 
by PCR using the Hot Start PCR kit from New England Biolabs. The sequence of PCR 
primers for confirmation of KRASG12D and heterozygous or knockout PKCε backgrounds 
were provided from the Jackson Laboratory and the Messing laboratory respectively. 
PCR primers for confirmation of KRASG12D were 5′-GTCGACAAGCTCATGCGGGTG, 
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5′-CCTT TACAAGCGCACGCAGACTGTAG and 5′-
AGCTAGCCACCATGGCTTGAGTA AGTCTGCA. For PKCε the primers were 5′-
ACATGCAGAATGAGTACCGG-3′, 5′-TCAACATCTCCTGGTGGAAC-3′ and 5′-
AATATGCGAAGTGGACCTCG-3′. 
 
Ad-Cre infections 
Recombinant adenovirus encoding Cre recombinase (Ad-Cre) was purchased 
from the University of Pennsylvania Gene Transfer Vector Core. 6 to 8 week-old mice 
were infected intranasally with 100 µl of saline containing 3 × 1010 PFU Ad-Cre. 20 
minutes prior to injection of 0.5 µl of 2 mol/l CaCl2 was added to improve gene transfer 
to airway epithelia. Before injections mice were anesthetized with ketamine (100mg/kg). 
 
Histology and immunohistochemistry 
For histological evaluation, whole lungs were manually inflated and fixed with 
10% formalin and then embedded in paraffin blocks. Longitudinal sections of lung were 
stained with hematoxylin and eosin (H&E) and evaluated by Dr. Steven Albelda 
(University of Pennsylvania). Tumors were given histologic scores as 0 (minimal tumors 
seen), 1 (small patchy areas of tumors), and 2 (extensive lung tumors).  
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pTRE-PKCε  vector construction 
cDNA encoding for PKCε was excised from the pB.PKCε vector and ligated into 
a pTRE-tight vector using T4 DNA ligase (Life Technologies). Initially, the pB.PKCε 
vector was modified by inserting a linker containing MluI, ATG and HA epitope using 
restriction enzymes NotI and XhoI (New England Biolabs). This modification generated a 
sequence coding for Mlu-ATG-HA-XhoI- PKCε- Mlu in the pB.PKCε vector. For the 
pTRE-tight vector, a stop codon was added flanked with Mlu and NotI restriction sites. 
Finally, the ATG-HA-PKCε was released from the pB.PKCε vector by digesting with 
Mlu and ligated into the pTRE-tight vector. pTRE-PKCε plasmid was transformed into 
E.coli (DH5α) and was purified using QIAprep maxi kit (Qiagen) according to the 
manufacturer's instructions. The purified plasmid was digested with the restriction 
enzyme Mlu to confirm isolated clones for cDNA insert and the plasmid vector. Clones 
with the correct orientation of insertion were selected after sequencing and verified by 
vector mapping using various enzymes. For in vitro validation of PKCε expression, Cos-
1 cells (1 × 105 cells/well in 12-well plates) were transfected with 0.1 µg/µL of pTet-On 
and 0.4 µg/µL of pTRE-PKCε using Lipofectamine2000 (Invitrogen).  After 24 h, cells 
were treated with doxycycline (Clontech) at concentrations of 0.1, 1, 5 and 10 µg/µL. 
The expression of PKCε was also validated by transfecting pTRE-PKCε.  pTRE-PKCε 
was digested and linearized by PciI and bcgI to remove unnecessary backbone of the 
pTRE-tight vector and was submitted to the Wistar Institute Transgenic Mouse Facility 
for pronuclear injection. Chimeric mice were generated in S129/B6 background.  
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Southern blot  
Genomic DNA was digested overnight with BglII and subjected to electrophoresis 
on a 0.7 % agarose gel. DNA was transferred to Zeta-Probe GT (Biorad) nylon 
membrane. The membrane was UV crosslinked and prehybridized in ExpressHyb 
solution (Clontech) containing salmon sperm DNA at 600 C.  The 239 base pair fragment 
of the plasmid pB.PKCε digested with PstI and BamHI was used as probe, radiolabeled 
using Exo (-) Klenow DNA polymerase (Biorad) and hybridized with DNA on the 
membrane in ExpressHyb solution overnight at 600 C.  The membrane was exposed to X-
ray film and visualized by autoradiography. 
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CHAPTER 5: Conclusions and Future Directions 
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This thesis work established the importance of PKC isozymes in the initiation and 
progression of lung cancer. PKC isozymes were found to regulate drug resistance, NF-κΒ 
pathway activation, and KRAS-driven lung tumorigenesis. We showed for the first time 
that PKC isozymes are implicated in the selective and adaptive mechanisms that are 
responsible for acquired resistance to molecular-targeted therapy. Our results indicate 
altered expression of PKCα and PKCδ in NSCLC cells resistant to erlotinib. 
Furthermore, overexpression of PKCα and down-regulation of PKCδ are required to 
induce erlotinib resistance. We also provided data showing that PKCα is essential for the 
maintenance of mesenchymal phenotype observed in erlotinib-resistant cells. Similar to 
drug resistance, inflammation is another key factor that contributes to the progression of 
lung cancer. Our data indicate that PKCα is a positive regulator of NF-κΒ signals in 
NSCLC cells, suggesting its role in the promotion of inflammation. PKCα regulates key 
steps of the canonical NF-κΒ pathway activation, including IκΒα phosphorylation, NF-
κΒ promoter activity, NF-κΒ DNA binding, and expression of NF-κΒ responsive genes 
involved in cell survival, motility, angiogenesis, and inflammation. The role of PKCs in 
lung cancer is not limited to disease progression, as we also identified the requirement for 
another PKC isozyme, PKCε, in the development of KRAS-driven lung tumor formation. 
By generating a mouse model that expresses mutant KRAS in a null PKCε background, 
we demonstrated that PKCε is required for KRAS-driven lung tumorigenesis. 
Resistance to therapy has been a major hurdle in lung cancer treatment. 
Identification of mechanisms associated with acquired resistance presents a strategy to 
overcome this hurdle. Our data in Chapter 2 provides compelling evidence for the use of 
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PKCα inhibitors in combination with erlotinib. Inhibition of PKCα using 
pharmacological inhibitors or with RNA interference significantly enhanced the 
sensitivity of NSCLC cells to erlotinib. PKCα was also shown to modulate its effect on 
erlotinib sensitivity, in part, by regulating the expression of PKCδ. Overexpression of 
PKCα in erlotinib-sensitive cells led to down-regulation of PKCδ, suggesting that the 
low levels of PKCδ seen in the erlotinib-resistant cells could have been driven by the 
overexpression in PKCα. Furthermore, reconstitution of PKCδ in erlotinib-resistant cells 
enhanced their sensitivity to erlotinib, thus underscoring the importance of PKCδ down-
regulation in acquired resistance to erlotinib therapy. 
Chapter 2 of this thesis also provides insight into how PKCα could be implicated 
in the selective mechanism that induces resistance to erlotinib. As previously 
documented, erlotinib-resistant cells have elevated expression of genes associated with 
EMT and display morphological changes that are reminiscent of the mesenchymal 
phenotype [212]. Our results demonstrated that although PKCα does not affect the 
expression of the epithelial marker E-cadherin, it regulates the expression of genes 
implicated in the induction of the mesenchymal phenotype, such as vimentin and Snail. 
The mechanisms through which PKCα acts to regulate the expression of genes associated 
with mesenchymal phenotype in lung cancer cells are yet to be determined. Recent 
studies in breast cancer revealed that PKCα preferentially supports the maintenance of 
mesenchymal cell state through its regulation of the transcription factor FRA1 (Fos-
related antigen 1). Whether a similar mechanism operates in lung cancer remains to be 
determined. A potential transcription factor that could be involved in PKCα-dependent 
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expression of EMT markers in NSCLC cells is NF-κB. Studies have identified known 
EMT marker genes such as vimentin, Snail and Zeb2 as target genes of NF-κB in several 
cancer types [9, 33, 103, 200] and in Chapter 3 of this thesis, we have established that 
PKCα-mediated regulation of NF-κB is required for the expression of NF-κB responsive 
genes in NSCLC cells. It would be important to determine if PKCα-dependent NF-κB 
activation is required for the transcription of vimentin, Snail, Twist and Zeb2 in erlotinib-
resistant cells. 
Our results also indicate that a subpopulation of erlotinib naive cells that express 
the mesenchymal surface marker CD44 exhibit higher levels of PKCα expression 
compared to the cell population where CD44 is absent. It would be interesting to see if 
stable overexpression of PKCα could increase the expression of CD44 as well as the 
expression of genes associated with the mesenchymal phenotype. Several studies have 
shown that cells undergoing EMT become aggressive and develop resistance to therapies. 
Conversely, EMT can be induced as a consequence of exposure to therapeutic drugs 
[182]. Our model of erlotinib-resistant cells presents yet a different mechanism for drug 
resistance where EMT and drug resistance co-exist, but do not have a causal relationship. 
As previously reported [212], depletion of genes associated with the mesenchymal 
phenotype did not alter the sensitivity to erlotinib, and erlotinib naive cells possess a 
subpopulation that already underwent EMT.  
The cells we used as a model for erlotinib resistance have high levels of TGF-β 
compared to the parental erlotinib-sensitive cells. TGF-β signaling is required and 
sufficient for the induction of erlotinib resistance and EMT in erlotinib-resistant cells and 
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our results revealed that TGF-β signaling drives the expression of PKCα in these cells. 
To assert the explicit dependence of PKCα expression on TGF-β, it is important to 
determine if inhibiting TGF-β levels in erlotinib-resistant cells to the level observed in 
the parental erlotinib-sensitive cells could decrease PKCα expression. Although the 
mechanism by which overexpression of PKCα mediates erlotinib resistance and EMT 
remains to be determined, we propose a model implicating PKCα in the transition from 
epithelial to mesenchymal cells and drug resistance in NSCLC cells (Fig. 5.1). 
 
Figure 5.1 Proposed model for PKCα-mediated erlotinib resistance in NSCLC cells 
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In Chapter 3, we demonstrated an additional role of PKCα in cellular processes 
implicated in lung cancer progression. PKCα regulates the activation of the NF-κΒ 
pathway in response to IL-1β. Inhibition of PKCα resulted in decreased IκΒα 
phosphorylation, indicating that it regulates the canonical NF-κΒ pathway. The effect 
was further supported by the observation that PKCα inhibition blocks NF-κΒ 
translocation and DNA binding. Activation of NF-κΒ is required for the induction of 
genes in response to IL-1β including pro-inflammatory genes. Our findings indicate that 
PKCα-mediated activation of NF-κΒ by IL-1β results in up-regulation of NF-κΒ-
responsive genes such as MMP9, COX-2 and IL-8. These findings suggest that PKCα 
could play an important role in promoting lung cancer progression that results from 
chronic inflammation. 
Future experiments must be done to identify the mechanism for PKCα-mediated 
activation of NF-κB in response to IL-1β. PKCs translocates from the cytosol to the 
plasma membrane upon activation. We can use real-time microscopy to assess whether 
IL-1β could induce changes in the subcellular localization of PKCα using a GFP-fused 
PKCα construct. If PKCα translocates to the plasma membrane upon IL-1β stimulation, 
it could potentially associate with IL-1R, the receptor for IL-1β. Indeed, an analogous 
mechanism was recently discovered by our laboratory for PKCε and the receptor for 
TNFα [54]. Immunoprecipitation of IL-1R from H460 cells will show whether 
endogenous PKCα coimmunoprecipitates with this receptor. If PKCα associates with the 
IL-1R, we speculate that IL-1β treatment will enhance that association. PKCα could also 
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be involved in the activation of NF-κB through phosphorylation of IKKs or 
phosphorylation of the RelA subunit important for the localization of the p50/RelA dimer 
to the nucleus. In vitro kinase assay could be utilized to determine if PKCα directly 
phosphorylates the IKK complex or the RelA subunit in NSCLC cells. These potential 
mechanisms are summarized in Fig. 5.2. 
 
 
Figure 5.2 Proposed model for the regulation of the canonical NF-κB pathway by 
PKCα  in NSCLC cells. 
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The work presented in this thesis also highlights the importance of PKC isozymes 
in lung cancer initiation. Previous studies from our lab established a key role for PKCε in 
lung cancer progression in KRAS mutant NSCLC cell lines and xenograft models [25, 
26]. In Chapter 4, we further demonstrated the requirement of PKCε for KRAS-induced 
lung tumor formation in a mouse model where mutant KRAS is expressed in a PKCε-null 
background. Indeed, genetic ablation of PKCε significantly attenuated tumor formation in 
KRAS mutant mice. Future experiments include determining what role PKCε plays in the 
maintenance of KRAS-induced lung tumors, as well as what mechanisms and 
downstream effectors of PKCε mediate KRAS signaling. 
It would also be important to determine whether overexpression of PKCε 
accelerates KRAS-driven lung tumor formation, and if by itself, is sufficient to induce 
precancerous or cancerous lesions in the lungs. We generated a mouse model that 
specifically expresses PKCε in the lungs when crossed with SPC-rtTA transgenic mice. 
Future experiments could use this model to generate KRAS mutant mice that overexpress 
PKCε in the lungs. We speculate that overexpression of PKCε in the lungs leads to the 
formation of preneoplastic and neoplastic lesions. On the basis of our preliminary results 
from bitransgenic KRASG12D;PKCε-/- mice, we also expect that overexpression of PKCε 
accelerates tumor formation and increases tumor incidence in the lungs.  
In conclusion, the data presented in this thesis has further established the 
significance of PKC isozymes in lung cancer development. Our work has identified the 
requirement of PKCα in selective and adaptive processes that result in the loss of 
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erlotinib sensitivity. We further established the importance of PKCα in the progression of 
NSCLC by demonstrating its regulation of the NF-κΒ pathway. Our results support the 
use of PKCα inhibitors for lung cancer patients with indications of TKI resistance and 
hyperactivation of the NF-κB pathway. Additionally, our work gives insights into the role 
of PKC isozymes in the initiation of lung cancer. We identified the requirement of 
PKCε signaling in KRAS-driven lung tumor formation. Pharmaceutical companies have 
been interested in the development of PKCε specific inhibitors for cancer treatment [38] 
and our results corroborate that PKCε specific inhibitors can be effective candidates for 
lung cancer prevention and treatment. 
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